var title_f20_8_20608="Insect in the external auditory canal";
var content_f20_8_20608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Insect in the external auditory canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 498px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of a tick (black arrow) in the external auditory ear canal and immediately adjacent to the tympanic membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20608=[""].join("\n");
var outline_f20_8_20608=null;
var title_f20_8_20609="Traumatic disruption of the diaphragm on plain film and CT";
var content_f20_8_20609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Traumatic disruption of the diaphragm on plain film and CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Traumatic disruption of the left hemidiaphragm is shown on the plain chest film and computed tomography (CT) of the chest. The anteroposterior view of the chest (A) shows the herniated stomach. The course of the nasogastric tube is aberrant with its tip (arrowhead) positioned cranially. In the CT scan (B),&nbsp;the tip&nbsp;of the nasogastric tube (arrowhead) is within the&nbsp;abnormally positioned&nbsp;stomach (arrows), which is filled with food and fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20609=[""].join("\n");
var outline_f20_8_20609=null;
var title_f20_8_20610="Breast mass algorithm";
var content_f20_8_20610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    Palpable mass detected or confirmed by clinician*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 793px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If the physician does not concur with the patient regarding the presence of a mass, confirm that routine screening is up to date, and advise the patient to return if concern persists.",
"     <br>",
"      &bull; Patients should be informed about their options for image-guided core needle biopsy.",
"      <br>",
"       &Delta; Consider referral to surgeon for excision of mass &gt;2 cm.",
"       <br>",
"        &loz; Ductal carcinoma in situ or invasive cancer.",
"        <br>",
"         &sect; Image-guided core needle biopsy or ultrasound after two cycles at discretion of radiologist.",
"         <br>",
"          &yen; Lesions that may fit this category include LCIS, atypical lobular hyperplasia, atypical ductal hyperplasia, radial scar (benign sclerosing lesion), some papillary lesions, mucin-producing lesions, and potential phyllodes tumor.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Copyrighted and used with permission of the Risk Management Foundation of the Harvard Medical Institutions, all rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20610=[""].join("\n");
var outline_f20_8_20610=null;
var title_f20_8_20611="Mediastinal goiter MRI I";
var content_f20_8_20611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63277%7EPULM%2F75079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63277%7EPULM%2F75079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal goiter displacing the trachea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial T1-weighted section shows a soft tissue mass due to mediastinal goiter (white arrow) displacing the trachea (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal goiter on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A coronal T1-weighted section through a mediastinal goiter (long arrow) shows it to be contiguous with the left lobe of the thyroid (short arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20611=[""].join("\n");
var outline_f20_8_20611=null;
var title_f20_8_20612="Dorsal foot anatomy";
var content_f20_8_20612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dorsal foot anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 541px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The path of dorsal arteries (red) and nerves (green) to the toes is shown. Each digit is innervated by four digital nerves; the plantar arteries and nerves are not shown in this figure. In order to achieve a complete anesthetic effect, it is necessary to block all four nerves. For a complete block of the great toe, there are additional branches that come up the dorsal aspect of the great toe that can be missed if anesthetic is only injected laterally and medially.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20612=[""].join("\n");
var outline_f20_8_20612=null;
var title_f20_8_20613="Pseudoephedrine: Pediatric drug information";
var content_f20_8_20613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pseudoephedrine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"    see \"Pseudoephedrine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/63/10229?source=see_link\">",
"    see \"Pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Children's Nasal Decongestant [OTC];",
"     </li>",
"     <li>",
"      Nexafed&reg; [OTC];",
"     </li>",
"     <li>",
"      Oranyl [OTC];",
"     </li>",
"     <li>",
"      Silfedrine Children's [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; 12 Hour [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; 24 Hour [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; Maximum Strength Nasal Decongestant [OTC];",
"     </li>",
"     <li>",
"      Sudo-Tab&reg; [OTC];",
"     </li>",
"     <li>",
"      SudoGest 12 Hour [OTC];",
"     </li>",
"     <li>",
"      SudoGest Children's [OTC] [DSC];",
"     </li>",
"     <li>",
"      SudoGest [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil Decongestant;",
"     </li>",
"     <li>",
"      Benylin&reg; D for Infants;",
"     </li>",
"     <li>",
"      Contac&reg; Cold 12 Hour Relief Non Drowsy;",
"     </li>",
"     <li>",
"      Drixoral&reg; ND;",
"     </li>",
"     <li>",
"      Eltor&reg;;",
"     </li>",
"     <li>",
"      PMS-Pseudoephedrine;",
"     </li>",
"     <li>",
"      Pseudofrin;",
"     </li>",
"     <li>",
"      Robidrine&reg;;",
"     </li>",
"     <li>",
"      Sudafed&reg; Decongestant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Decongestant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"      see \"Pseudoephedrine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;4 years: 1 mg/kg/dose every 6 hours; maximum single dose: 15 mg (Gentile, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-5 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s recommendation: 15 mg every 4-6 hours; maximum dose: 60 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternative dosing: 1 mg/kg/dose every 6 hours; maximum dose: 15 mg (Gentile, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 years: 30 mg every 4-6 hours; maximum dose: 120 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 60 mg every 4-6 hours; maximum dose: 240 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: 120 mg every 12 hours or 240 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed&reg; 12 Hour: 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrochloride: 30 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children's Nasal Decongestant: 30 mg/5 mL (118 mL) [contains sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silfedrine Children's: 15 mg/5 mL (118 mL, 237 mL) [ethanol free, sugar free; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed&reg; Children's: 15 mg/5 mL (118 mL) [ethanol free, sugar free; contains menthol, sodium 5 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride: 30 mg/5 mL (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SudoGest Children's: 15 mg/5 mL (118 mL [DSC]) [ethanol free, sugar free; contains sodium 5 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nexafed&reg;: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oranyl: 30 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed&reg; Maximum Strength Nasal Decongestant: 30 mg [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudo-Tab&reg;: 30 mg [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SudoGest: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SudoGest: 60 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sudafed&reg; 24 Hour: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SudoGest 12 Hour: 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release products",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with water or milk to decrease GI distress; swallow timed release tablets or capsules whole, do not chew or crush; Sudafed&reg; 24 Hour tablet may not completely dissolve and appear in stool",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary symptomatic relief of nasal congestion due to common cold, upper respiratory allergies, and sinusitis; also promotes nasal or sinus drainage (immediate release formulations: FDA approved in ages &gt;4 years and adults; extended release formulations: FDA approved in ages &gt;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F215371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sudafed&reg; may be confused with sotalol, Sudafed PE&reg;, Sufenta&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F215369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, cardiovascular collapse with hypotension, hypertension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, confusion, coordination impaired, dizziness, drowsiness, excitability, fatigue, hallucination, headache, insomnia, nervousness, neuritis, restlessness, seizure, transient stimulation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dry throat, ischemic colitis, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficult urination, dysuria, polyuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Chest/throat tightness, dry nose, dyspnea, nasal congestion, thickening of bronchial secretions, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pseudoephedrine or any component; MAO inhibitor therapy, severe hypertension, severe coronary artery disease",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hyperthyroidism, diabetes mellitus, prostatic hypertrophy, mild-moderate hypertension, arrhythmias, renal impairment, seizure disorders.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy for the use of cough and cold products in children &lt;2 years of age is limited. Serious adverse effects including death have been reported. The FDA notes that there are no approved OTC uses for these products in children &lt;2 years of age. Healthcare providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient. Some products contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use of sodium benzoate containing products in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5630944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of pseudoephedrine during the first trimester may be associated with a possible risk of gastroschisis, small intestinal atresia, and hemifacial microsomia due to pseudoephedrine's vasoconstrictive effects; additional studies are needed to define the magnitude of risk. Single doses of pseudoephedrine were not found to adversely affect the fetus during the third trimester of pregnancy (limited data); however, fetal tachycardia was noted in a case report following maternal use of an extended release product for multiple days. Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy. Oral pseudoephedrine should be avoided during the first trimester.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Directly stimulates alpha-adrenergic receptors of respiratory mucosa causing vasoconstriction; directly stimulates beta-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Decongestant: Oral: 30 minutes (Chua, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Decongestant: Oral: ~1-2 hours (Chua, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Immediate release tablet: 3-8 hours (Chua, 1989)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid (Simons, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: ~2.5 L/kg (Simons, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 2.64-3.51 L/kg (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Undergoes n-demethylation to norpseudoephedrine (active) (Chua, 1989; Kanfer, 1993); hepatic (&lt;1%) (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Varies by urine pH and flow rate; alkaline urine decreases renal elimination of pseudoephedrine (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: ~3 hours (urine pH ~6.5) (Simons, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 9-16 hours (pH 8); 3-6 hours (pH 5) (Chua, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: Immediate release tablet: ~2 hours (Simons, 1996)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Immediate release tablet: 1-3 hours (dose-dependent) (Kanfer, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine (43% to 96% as unchanged drug, 1% to 6% as active norpseudoephedrine); dependent on urine pH and flow rate; alkaline urine decreases renal elimination of pseudoephedrine (Kanfer, 1993)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F13702592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Because ephedrine and pseudoephedrine have been used to synthesize methamphetamine, the DEA has placed them in the category of &ldquo;Schedule Listed Products&rdquo;; restrictions are in place to reduce the potential for misuse (diversion) and abuse (eg, storage requirements, additional documentation of sale); the DEA limit for a single transaction to a single individual for drug products containing ephedrine or pseudoephedrine is 3.6 g/24 hours, 9 g/30 days, or if mail-order transaction 7.5 g/30 days.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/8/20613/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chua SS, Benrimoj SI, and Triggs EJ, \"Pharmacokinetics of Non-Prescription Sympathomimetic Agents,\"",
"      <i>",
"       Biopharm Drug Dispos",
"      </i>",
"      , 1989, 10(1):1-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/8/20613/abstract-text/2647163/pubmed\" id=\"2647163\" target=\"_blank\">",
"        2647163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gentile DA, Friday GA, and Skoner DP, \"Management of Allergic Rhinitis: Antihistamines and Decongestants,\"",
"      <i>",
"       Immunol Allergy Clin NA",
"      </i>",
"      , 2000, 20(2):355-68.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kanfer I, Dowse R, and Vuma V, \"Pharmacokinetics of Oral Decongestants,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1993, 13(6 Pt 2):116-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/8/20613/abstract-text/7507589/pubmed\" id=\"7507589\" target=\"_blank\">",
"        7507589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FE, Gu X, Watson WT, et al, &ldquo;Pharmacokinetics of the Orally Administered Decongestants Pseudoephedrine and Phenylpropanolamine in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 129(5):729-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/8/20613/abstract-text/ 8917241 /pubmed\" id=\" 8917241 \" target=\"_blank\">",
"        8917241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Werler MM, \"Teratogen Update: Pseudoephedrine,\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2006, 76(6):445-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/8/20613/abstract-text/16933214/pubmed\" id=\"16933214\" target=\"_blank\">",
"        16933214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12747 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-D795AC79FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20613=[""].join("\n");
var outline_f20_8_20613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215332\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215333\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061613\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061608\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215313\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215299\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061617\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061616\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215371\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215369\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061621\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061607\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061606\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299959\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215308\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630944\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061605\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061619\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061620\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13702592\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12747\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12747|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=related_link\">",
"      Pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/63/10229?source=related_link\">",
"      Pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_8_20614="Megakaryocyte responsiveness";
var content_f20_8_20614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F81722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F81722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Megakaryocyte response to changes in platelet count",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 367px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The physiologic response of bone marrow megakaryocytes in mice made acutely thrombocytopenic by the injection of antiplatelet antibody (Panel A) or made thrombocytotic by the transfusion of platelets (Panel C) and compared with untreated mice (Panel B) (x16). The number, size, and nuclear lobulation of bone marrow megakaryocytes increased during thrombocytopenia and decreased during thrombocytosis when compared with normal animals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Penington, DG, Olsen, TE, Br J Haematol 1970; 18:447.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20614=[""].join("\n");
var outline_f20_8_20614=null;
var title_f20_8_20615="Establishing and maintaining a therapeutic relationship in psychiatric practice";
var content_f20_8_20615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Establishing and maintaining a therapeutic relationship in psychiatric practice",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20615/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20615/contributors\">",
"     Andrew Skodol, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20615/contributors\">",
"     Donna Bender, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20615/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20615/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20615/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20615/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/8/20615/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14925100\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between a clinician and a patient in psychotherapy plays a central role in alleviating symptoms and fostering character change [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/1\">",
"     1",
"    </a>",
"    ]. The treatment relationship can be a potentially powerful vehicle for patient improvement, as it can provide a supportive environment for exploration, and because issues that come up in this context can be processed in a very immediate and instructive way.",
"   </p>",
"   <p>",
"    This topic describes common treatment issues, problems, and opportunities in the clinician-patient therapeutic relationship. Approaches to the therapeutic relationship in patients with personality disorders are described separately. The epidemiology, clinical manifestations, diagnosis, and treatment of specific personality disorders are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3896?source=see_link\">",
"     \"Approaches to the therapeutic relationship in patients with personality disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=see_link\">",
"     \"Personality disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=see_link\">",
"     \"Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=see_link\">",
"     \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3769?source=see_link\">",
"     \"Treatment of antisocial personality disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=see_link\">",
"     \"Borderline personality disorder: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925107\">",
"    <span class=\"h1\">",
"     THERAPEUTIC RELATIONSHIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever an individual decides to undertake mental health treatment of any sort, a relationship is begun with the treating clinician. Several components of the relationship can influence the outcome of treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How the relationship is established and evolves",
"     </li>",
"     <li>",
"      How the patient experiences, reacts to and uses the relationship",
"     </li>",
"     <li>",
"      How the clinician engages in and manages the relationship",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most people seek help because they are having difficulties functioning, often with self-perception and interpersonal situations. &nbsp;Characteristic difficulties will likely manifest in the treatment relationship as well, and this provides a context in which the patient can learn how certain thought, behavioral, and emotional patterns may not be serving them well. The therapeutic relationship offers an opportunity for new interpersonal experiences with a clinician invested in being helpful and serving the patient&rsquo;s best interests. &nbsp;For some patients, mental health treatment provides a relatively rare opportunity to speak with someone who listens attentively and takes a genuine interest in them.",
"   </p>",
"   <p>",
"    Clinicians need to be aware that many patients have difficulties that make it more challenging to engage in therapeutic work. The clinician&rsquo;s patience and skill will be necessary to engage these patients in a meaningful way. &nbsp;",
"   </p>",
"   <p>",
"    A helpful component of the psychoanalytic definition of a therapeutic relationship suggests that there is a &ldquo;split&rdquo; in the patient&rsquo;s &ldquo;ego,&rdquo; which allows the therapist to work with the patient&rsquo;s healthier aspects against resistance and pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/2\">",
"     2",
"    </a>",
"    ]. This definition acknowledges that there will be pathological parts of the patient&rsquo;s personality functioning that may interfere with the clinician&rsquo;s attempt to help, along with more adaptive aspects of the patient&rsquo;s character that may be available for the work of the treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89663786\">",
"    <span class=\"h2\">",
"     Therapeutic alliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important component of the treatment relationship between patient and therapist is the therapeutic or working alliance, a concept originating in psychoanalytic theory that has been operationalized and measured in research examining the relationship between the alliance and patient outcomes. A model of the therapeutic alliance identifies three interdependent components of a therapeutic alliance: bond, tasks, and goals. The bond is the quality of the relationship formed in the treatment dyad that mediates whether the patient will address the tasks inherent in working toward the goals of a particular treatment approach [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Forming an alliance may not be difficult with a relatively healthy patient. Establishing a therapeutic alliance with more disturbed patients may be one of the primary goals of treatment. There may be different phases in the development of an alliance as treatment progresses. Stages in alliance development have been observed in long-term psychotherapy of patients with borderline personality disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contractual (behavioral) &mdash; An initial agreement between the patient and therapist on treatment goals and on each of their roles in achieving them.",
"     </li>",
"     <li>",
"      Relational",
"      <span class=\"nowrap\">",
"       (affective/empathic)",
"      </span>",
"      &mdash; An emphasis on developing a relationship in which the patient experiences the therapist as caring, understanding, genuine, and likable.",
"     </li>",
"     <li>",
"      Working",
"      <span class=\"nowrap\">",
"       (cognitive/motivational)",
"      </span>",
"      &mdash; The patient joins the therapist as a reliable collaborator to help the patient understand herself or himself.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A lengthy initial alliance-building period may be required with a significantly disturbed patient to reach a point at which work leading to substantive and enduring personality change can occur.",
"   </p>",
"   <p>",
"    A meta-analysis of 79 studies found a moderately strong relationship between therapeutic alliance and patient outcome that was consistent across a wide range of instruments based on varying constructs of therapeutic&nbsp;alliance, and across diverse types of mental health treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925121\">",
"    <span class=\"h1\">",
"     PROBLEMS IN THE THERAPEUTIC RELATIONSHIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research findings suggest that unaddressed problems in the therapeutic relationship may lead to premature treatment termination by a patient [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. &ldquo;Strains&rdquo; are problems in the relationship that can undermine treatment effectiveness; &ldquo;ruptures&rdquo; are severe disruptions that threaten treatment continuity itself. Skillfully addressing ruptures may strengthen the relationship between a therapist and patient; the occurrence of rupture-repair episodes during treatment has been associated with better treatment outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7664012\">",
"    <span class=\"h2\">",
"     Strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strains in the clinician-patient relationship are inevitable and occur more frequently than is apparent to clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/9\">",
"     9",
"    </a>",
"    ]. One study found that patients frequently did not express negative thoughts and feelings that they had about their therapists. Even experienced therapists were aware of unarticulated negative material only 45 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/10\">",
"     10",
"    </a>",
"    ]. Therapist awareness of patients&rsquo; negative feelings towards them may also create problems if the therapist becomes defensive, negative, or more rigid in applying treatment techniques, rather than being open and flexible in response [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7664005\">",
"    <span class=\"h2\">",
"     Ruptures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should be alert to ruptures and adopt the attitude that these events may be excellent opportunities to engage a patient in a collaborative effort to observe and learn about him- or herself [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/11\">",
"     11",
"    </a>",
"    ]. Two subtypes of ruptures in the therapeutic relationship have been described: withdrawal and confrontation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Withdrawal can be subtle. A patient may withhold important information because of lack of trust or for fear of feeling humiliated. He or she may intellectualize (eg, talking excessively about other people) or may repeatedly change the subject. Withdrawal behaviors may be more common in patients who are overly compliant, such as those with dependent or obsessive-compulsive personality traits or disorders, or those who are uncomfortable about interpersonal relations, such as those with avoidant personality traits or disorder. Patients who experience excessive shame, such as those with borderline personality disorder, may withhold information out of fear of being negatively judged by the therapist.",
"     </li>",
"     <li>",
"      Confrontations are more overt manifestations of relationship problems; they include direct complaints about various aspects of therapy or criticism of the therapist. Some confrontations may be dramatic, for example, a patient who storms out of session in a rage or leaves an angry message on a therapist&rsquo;s answering machine. Confrontation ruptures are more likely to occur in the treatment of severely interpersonally impaired patients, such as those with borderline, narcissistic, or paranoid personality traits or disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925339\">",
"    <span class=\"h1\">",
"     COMMON TREATMENT ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925240\">",
"    <span class=\"h2\">",
"     Confidentiality",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients must be afforded confidentiality in psychotherapy, however, there may be legal or clinical limits to its protection that the patient should be informed of at the outset of treatment. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many jurisdictions require that therapists warn others when a patient makes a specific threat to harm someone and report instances of child abuse.",
"     </li>",
"     <li>",
"      If a patient tells a therapist that he or she is suicidal, the therapist may be obligated to enlist the help of family members or the police in having the patient hospitalized and will undoubtedly provide information about the patient&rsquo;s history and treatment to emergency room or hospital staff.",
"     </li>",
"     <li>",
"      Health insurers may require clinicians to provide information about the patient&rsquo;s symptoms and diagnosis to authorize or pay for the patient&rsquo;s treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any of these situations can result in a rupture in the clinician-patient relationship. The clinician should be mindful of this possibility and attempt to reach a mutually acceptable understanding of the meaning of the event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925247\">",
"    <span class=\"h2\">",
"     Fee setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an individual therapist&rsquo;s private practice, particularly when the patient directly pays for therapy, the therapeutic situation is a transaction between the therapist and patient. The treatment provider typically charges the patient for his or her time. Fees should be discussed at the first visit and agreed upon. The timing of bills and the expected payment date should also be discussed. A therapist may elect to reduce his or her fees, based on the patient&rsquo;s financial circumstances, but should not inflate a usual fee because a patient can pay more. If fees are not paid on time, nonpayment and its significance should be brought up by the therapist and discussed. If nonpayment is due the patient&rsquo;s inability to pay for treatment, termination of treatment with a referral to an affordable treatment source is likely to be a better option than allowing a patient to become financially indebted to the therapist.",
"   </p>",
"   <p>",
"    For patients who use health insurance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are treated in a clinic or hospital setting, matters may be somewhat more complicated by the policies of third-party payers and the provider organization. The organization&rsquo;s fee policies should be explained and the patient&rsquo;s insurance or personal resources should be determined. &nbsp;",
"   </p>",
"   <p>",
"    It is common for patients to view the fee and the business part of therapy through the lens of their personalities. A patient with narcissistic tendencies may devalue a therapist who does not have a fee commensurate with his or her inflated self-image. Some patients may experience the need to pay for treatment as an indication that the therapist is uncaring, while others may readily pay any amount, affordable or not, to assure the continuation of the relationship. An obsessive-compulsive patient may assume that paying his or her fee is sufficient evidence of active engagement in a treatment and not feel the need to pursue exploration or understanding of painful emotions.",
"   </p>",
"   <p>",
"    A policy should be established regarding visits missed by a patient. Issues include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Under what circumstances would a patient be charged for a missed visit?",
"     </li>",
"     <li>",
"      How much advanced notice does a patient need to give for cancelling a visit?",
"     </li>",
"     <li>",
"      Will a make-up session be offered if a visit is cancelled or missed?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925254\">",
"    <span class=\"h2\">",
"     Personal disclosures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapists vary widely in the degree to which they are willing to disclose personal information to their patients. Some therapists choose not to answer any questions about their personal lives, while others engage in self-disclosure as if with a friend or colleague. For most patients, neither extreme is ideal. For some patients, the refusal to answer personal questions may be viewed as rigid and withholding and drive a patient away. At the same time, being excessively revealing may be threatening and cause a patient intense fear or anxiety about the therapist&rsquo;s boundaries and ability to establish a safe environment. It is reasonable to answer questions relevant to the patient&rsquo;s seeking treatment, such as the therapist&rsquo;s training and the nature of the treatment to be provided. It is usually not justified for the therapist to reveal personal details of his or her life to patients such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The therapist&rsquo;s family composition",
"     </li>",
"     <li>",
"      Living arrangements",
"     </li>",
"     <li>",
"      Income",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Between these two extremes are many possibilities, which may vary depending on both the patient and the therapist. A well-trained therapist with a reasonable degree of self-understanding will ideally carefully consider the reasons for a patient&rsquo;s interest in obtaining details about the therapist&rsquo;s personal life and will have a specific rationale for disclosure that is within the patient&rsquo;s interests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925261\">",
"    <span class=\"h2\">",
"     Gifts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gifts are a common way of expressing gratitude to another person who has helped. Patients frequently want to give gifts to their therapists. Some therapists refrain from taking gifts, insisting that the fee paid is sufficient reward for their time and effort. Some patients may perceive this response as a rejection, but this can and should be addressed. Other therapists accept reasonable gifts from a patient when he or she concludes that it is therapeutically important for the patient to express him or herself in this manner and have the gift be received. As with disclosures, the important point is to try to understand the meaning of gift-giving for a particular patient and to attempt to have the patient understand it too.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925268\">",
"    <span class=\"h2\">",
"     Boundary crossings and violations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotherapeutic treatment has specific rules guiding the appropriate behavior of therapists and of patients. These rules, often referred to as &ldquo;boundaries,&rdquo; are necessary for a patient to feel safe in a very intimate environment and to protect both the patient and the therapist from exploitation. As examples, the therapeutic transaction usually takes place in a controlled environment, has a set time and duration, and involves discussing patient problems. These factors have been referred to as the &ldquo;frame&rdquo; of the treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain rituals, such as whether to shake hands with a patient or not, vary by therapist, but can be appropriate if part of the therapist&rsquo;s standard practice. Other practices, such as those below, may differ by individual therapist or organizational policy, but may be helpful for certain patients if handled in a prudent and thoughtful fashion.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Accepting text message communications",
"     </li>",
"     <li>",
"      Returning phone calls on weekends",
"     </li>",
"     <li>",
"      Offering a tissue to a patient who has been crying",
"     </li>",
"     <li>",
"      Helping an elderly patient put on a coat",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There will be an occasional need to divert more extensively from the therapist&rsquo;s standard practice. As an example, a patient is stranded in a snowstorm with no access to transportation and needs a ride in the therapist&rsquo;s car.",
"   </p>",
"   <p>",
"    These are called boundary &ldquo;crossings&rdquo; because they clearly deviate from standard procedure, but they may not be disruptive to treatment because they are necessary, have a clear purpose or rationale, and are understood by both the therapist and patient. Boundary crossings are ideally based on sound clinical judgment, are discussed afterward between a patient and a therapist, and are documented in the therapist&rsquo;s records [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Boundary &ldquo;violations&rdquo; are more egregious deviations from protocol. As example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A therapist inappropriately hugs a patient or allows her to sit on his lap",
"     </li>",
"     <li>",
"      A therapist sees a patient outside of the treatment for dinner",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These violations are rarely if ever justified and undoubtedly do great damage to the relationship, the treatment, and the patient him or herself. Boundary violations are by definition exploitative of the patient and serve to gratify needs of the therapist. Sexual involvement of any kind with a patient is an unjustifiable boundary violation that can result in a malpractice suit and loss of professional licensure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925275\">",
"    <span class=\"h1\">",
"     RELEVANCE ACROSS TREATMENT PARADIGMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No matter what treatment paradigm a therapist uses, attention to the therapeutic relationship is critical. The therapist must monitor his or her thoughts and feelings closely, because interactions with difficult patients may often be provocative, inducing reactions that must be carefully managed. Although referred to as &ldquo;countertransference&rdquo; in the",
"    <span class=\"nowrap\">",
"     psychoanalytic/psychodynamic",
"    </span>",
"    tradition, monitoring and understanding one&rsquo;s own thoughts and feelings about a patient is applicable across all treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment approach and technique must be flexible so that interventions can be made appropriate to the individual patient&rsquo;s style. The relationship may otherwise be jeopardized and the patient will not benefit or may leave treatment altogether. As an example, a study of 78 patients with borderline personality disorder found that an interaction between the relationship and therapeutic techniques influenced patients&rsquo; course and outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3896?source=see_link\">",
"     \"Approaches to the therapeutic relationship in patients with personality disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925282\">",
"    <span class=\"h2\">",
"     Psychodynamic/psychoanalytic psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mixture of supportive and expressive (interpretive) elements occurs in every analysis or psychodynamic psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/16\">",
"     16",
"    </a>",
"    ]. The expressive, insight-oriented mode of assisting patients in uncovering unconscious conflicts, thoughts, or affects through interpretation or confrontation may be appropriate at times, whereas a more supportive approach of bolstering the patient&rsquo;s defenses and coping abilities is preferable in other circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link&amp;anchor=H4244440#H4244440\">",
"     \"Overview of psychotherapies\", section on 'Psychodynamic psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flexibility is recommended in adjusting between supportive and interpretive interventions according to the dynamics of a particular patient at a particular time given the patient&rsquo;s capacities and vulnerabilities. Interpretation of transference, long considered the heart of the psychoanalytic approach, can be counterproductive with more disturbed patients, most notably those with borderline and narcissistic tendencies, particularly in the initial phase of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It may be difficult to focus on more insight-oriented interventions with a patient with borderline impairments until that patient is assisted in achieving a safe, more stable relationship. The severely narcissistically impaired patient may similarly not be able to accept the analyst&rsquo;s interpretations of his or her unconscious motivations for quite some time, so that supportive, empathic communications may be more effective interventions in building a relationship by helping the patient feel heard and understood. Some obsessional patients may, conversely, benefit earlier in treatment by interpretations of the conflicts that may underlie the symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925289\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cognitive and cognitive-behavioral therapies are predicated on establishing a productive therapist-patient collaboration from very early in the treatment, which involves the patient&rsquo;s undertaking specific activities and &ldquo;homework&rdquo;. It is also important at the beginning of treatment to inform the patient about particular limits of confidentiality so that ruptures of this type can be minimized. Patients&rsquo; willingness and ability to participate constructively in these activities can vary significantly, depending upon personality style and severity of symptoms such as anxiety and depression. Patients with more severe personality psychopathology, such as borderline or narcissistic disturbances, are sometimes more difficult to engage in the therapeutic tasks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/19\">",
"     19",
"    </a>",
"    ]. To facilitate the therapeutic relationship when working with patients with personality disorders, work needs to directly address therapist-patient collaboration with clearly set boundaries, and to focus attention in treatment on the relationship itself when appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link&amp;anchor=H432862147#H432862147\">",
"     \"Overview of psychotherapies\", section on 'Cognitive and behavioral therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, dialectical behavior therapy (DBT) is commonly employed for highly self-harming patients with borderline personality disorder. Although DBT is a manualized, highly structured treatment with particular skills training tasks, the therapist needs to explore problems that arise in treatment and maintain a great deal of flexibility within the paradigm to achieve and maintain a therapeutic relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/20\">",
"     20",
"    </a>",
"    ]. There may be frequent occurrences of patient behaviors interfering with treatment ranging from missed sessions to multiple suicide attempts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=see_link&amp;anchor=H10#H10\">",
"     \"Borderline personality disorder: Treatment and prognosis\", section on 'Dialectical behavior therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925296\">",
"    <span class=\"h2\">",
"     Psychopharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research has found the therapeutic alliance to be associated with patient outcomes in pharmacotherapy as well as in psychotherapy. A study of 225 patients with depression treated with interpersonal psychotherapy, cognitive-behavioral therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    , or placebo found that the quality of the therapeutic alliance was significantly related to patient outcome for all treatment groups [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that the prescribing clinician should make every effort to involve the patient as a collaborator who engages actively in goal-setting as well as observing and evaluating the course of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/22\">",
"     22",
"    </a>",
"    ]. Such collaboration, like other therapeutic processes, may be affected by distortions in the patient&rsquo;s views of the clinician. Patients with paranoid tendencies may think the physician is trying to trick them, or to take control of their lives. Some patients who are prone to expressing their emotions through physical sensations or complaints, such as those with borderline or histrionic tendencies, might be hypersensitive to any possible side effects (real or imagined). They may argue with the prescriber about his or her competence. Some patients may become upset if the clinician decides that medication is not warranted, feeling slighted because they think their problems are not being taken seriously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925303\">",
"    <span class=\"h2\">",
"     Psychiatric hospital settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inpatient psychiatric care almost always involves a treatment team of multiple clinicians and aides assigned to an individual patient. This circumstance can be stabilizing in that it offers more intensive care than outpatient therapy, but it can also be potentially fraught with conflict if problems are not anticipated and managed. &nbsp;As an example, inpatients with borderline personality disorder may cause &ldquo;splitting&rdquo; in their relationships with members of the inpatient treatment team. This type of patient&rsquo;s mental world is often organized into",
"    <span class=\"nowrap\">",
"     black/white,",
"    </span>",
"    <span class=\"nowrap\">",
"     good/bad",
"    </span>",
"    polarities. Through interactions with various staff members, this internal world can be replayed externally, dividing staff member against staff member. The patient will present one self-representation to one or several team members and a very different representation to another [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20615/abstract/23\">",
"     23",
"    </a>",
"    ]. One group of staff members may be viewed as the &ldquo;good&rdquo; one by the patient and the other as the &ldquo;bad&rdquo; one, although these designations can flip precipitously in the patient&rsquo;s mind. The split can be enacted among team members as they begin to compete and to work at cross purposes. Communication and close collaboration among members of the inpatient or day-program treatment team are vital during every phase of this treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=see_link&amp;anchor=H9#H9\">",
"     \"Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis\", section on 'Interpersonal difficulties'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inpatient or day-program team also needs to productively collaborate with clinicians who provide the patient&rsquo;s outpatient treatment. Hospitalization may represent a significant rupture in the outpatient therapeutic relationship; however, the rupture does not necessarily indicate that the outpatient treatment was ineffective and must be terminated. Work may be needed to reestablish the continuity of the treatment relationship and to coordinate inpatient care with the patient&rsquo;s outpatient clinicians.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14925310\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The relationship between a clinician and a patient in psychotherapy plays a central role in alleviating symptoms or fostering character change. The therapeutic alliance is one of the most robust predictors of outcome in psychotherapy. Clinician skill and tact are necessary to build a productive relationship. (See",
"      <a class=\"local\" href=\"#H14925100\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should be prepared to make adjustments in their approach to patients to avoid or to address various strains or ruptures in the alliance that may occur. (See",
"      <a class=\"local\" href=\"#H14925121\">",
"       'Problems in the therapeutic relationship'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should monitor the therapeutic relationship in response to clinical interventions as a way to assess the effectiveness of a treatment approach, and to adjust the style and content of their interactions with the patient accordingly. (See",
"      <a class=\"local\" href=\"#H14925121\">",
"       'Problems in the therapeutic relationship'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Establishing a therapeutic relationship within any treatment paradigm requires empathy and acknowledgment of a patient&rsquo;s view of the treatment and the treatment relationship. (See",
"      <a class=\"local\" href=\"#H14925275\">",
"       'Relevance across treatment paradigms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several common issues that may strain the therapeutic relationship, but also provide opportunities for a therapist and patient to observe and learn about the patient&rsquo;s interpersonal relationships, include confidentiality, fee setting, personal disclosure, and gifts. (See",
"      <a class=\"local\" href=\"#H14925339\">",
"       'Common treatment issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Orlinsky DA, Grawe K, Parks BK. Process and outcome in psychotherapy: Noch einmal. In: Handbook of Psychotherapy and Behavior Change, 4th ed, Bergin AE, Garfield SL.  (Eds), Wiley, New York 1994. p.270.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/2\">",
"      Gutheil TG, Havens LL. The therapeutic alliance: Contemporary meanings and confusions. Int Rev Psychoanal 1979; 6:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/3\">",
"      Bordin ES. The generalizability of the psychoanalytic concept of the working alliance. Psychotherapy: Theory, Research and Practice 1979; 16:252.",
"     </a>",
"    </li>",
"    <li>",
"     Gunderson JG. Psychodynamic psychotherapy for borderline personality disorder. In: Psychotherapy for Personality Disorders, Gunderson JG, Gabbard GO.  (Eds), American Psychiatric Press, Washington, DC 2000. p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/5\">",
"      Martin DJ, Garske JP, Davis MK. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. J Consult Clin Psychol 2000; 68:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/6\">",
"      Samstag LW, Batchelder S, Muran JC, et al. Predicting treatment failure from in-session interpersonal variables. J Psychother Pract Res 1998; 5:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/7\">",
"      Safran JD, Muran JC, Eubanks-Carter C. Repairing alliance ruptures. Psychotherapy (Chic) 2011; 48:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/8\">",
"      Strauss JL, Hayes AM, Johnson SL, et al. Early alliance, alliance ruptures, and symptom change in a nonrandomized trial of cognitive therapy for avoidant and obsessive-compulsive personality disorders. J Consult Clin Psychol 2006; 74:337.",
"     </a>",
"    </li>",
"    <li>",
"     Safran JD, Muran JC. Negotiating the Therapeutic Alliance, Guilford, New York, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/10\">",
"      Hill CE, Thompson BJ, Cogar MC, et al. Beneath the surface of long-term therapy: therapist and client report of their own and each other&rsquo;s covert processes. J Couns Psychol 1993; 40:278.",
"     </a>",
"    </li>",
"    <li>",
"     The Working Alliance: Theory, Research, and Practice, Horvath AO, Greenberg LS.  (Eds), Wiley, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/12\">",
"      Gutheil TG, Gabbard GO. The concept of boundaries in clinical practice: theoretical and risk-management dimensions. Am J Psychiatry 1993; 150:188.",
"     </a>",
"    </li>",
"    <li>",
"     Gutheil TG. Boundary issues. In: Essentials of Personality Disorders, Oldham JO, Skodol AE, Bender DS.  (Eds), American Psychiatric Publishing, Washington, DC 2009. p.309.",
"    </li>",
"    <li>",
"     Gabbard GO. An overview of countertransference: theory and technique. In: Countertransference Issues in Psychiatric Treatment, Gabbard GO.  (Ed), American Psychiatric Press, Washington, DC 1999. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/15\">",
"      Spinhoven P, Giesen-Bloo J, van Dyck R, et al. The therapeutic alliance in schema-focused therapy and transference-focused psychotherapy for borderline personality disorder. J Consult Clin Psychol 2007; 75:104.",
"     </a>",
"    </li>",
"    <li>",
"     Gabbard GO. Psychodynamic Psychiatry in Clinical Practice, 4th ed, American Psychiatric Press, Washington, DC 2005.",
"    </li>",
"    <li>",
"     Winnicott DW. The Maturational Processes and the Facilitating Environment, Hogarth Press, London 1965.",
"    </li>",
"    <li>",
"     Kohut H. How Does Analysis Cure?, University of Chicago Press, Chicago, IL 1984.",
"    </li>",
"    <li>",
"     Tyrer P, Davidson K. Cognitive therapy for personality disorders. In: Psychotherapy for Personality Disorders, Gunderson JG, Gabbard GO.  (Eds), American Psychiatric Press, Washington, DC 2000. p.131.",
"    </li>",
"    <li>",
"     Linehan MM. Cognitive-Behavioral Treatment of Borderline Personality Disorder, Guilford, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/21\">",
"      Krupnick JL, Sotsky SM, Simmens S, et al. The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1996; 64:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/22\">",
"      Gutheil TG. The psychology of psychopharmacology. Bull Menninger Clin 1982; 46:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20615/abstract/23\">",
"      Gabbard GO. Splitting in hospital treatment. Am J Psychiatry 1989; 146:444.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14764 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20615=[""].join("\n");
var outline_f20_8_20615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14925310\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14925100\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14925107\">",
"      THERAPEUTIC RELATIONSHIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H89663786\">",
"      Therapeutic alliance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14925121\">",
"      PROBLEMS IN THE THERAPEUTIC RELATIONSHIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7664012\">",
"      Strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7664005\">",
"      Ruptures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14925339\">",
"      COMMON TREATMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14925240\">",
"      Confidentiality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14925247\">",
"      Fee setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14925254\">",
"      Personal disclosures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14925261\">",
"      Gifts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14925268\">",
"      Boundary crossings and violations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14925275\">",
"      RELEVANCE ACROSS TREATMENT PARADIGMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14925282\">",
"      Psychodynamic/psychoanalytic psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14925289\">",
"      Cognitive-behavioral therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14925296\">",
"      Psychopharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14925303\">",
"      Psychiatric hospital settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14925310\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42409?source=related_link\">",
"      Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3896?source=related_link\">",
"      Approaches to the therapeutic relationship in patients with personality disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10553?source=related_link\">",
"      Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42009?source=related_link\">",
"      Borderline personality disorder: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40824?source=related_link\">",
"      Personality disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3769?source=related_link\">",
"      Treatment of antisocial personality disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_8_20616="Neurologic sarcoidosis";
var content_f20_8_20616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic sarcoidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20616/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20616/contributors\">",
"     Barney J Stern, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20616/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20616/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20616/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20616/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/8/20616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications occur in approximately 5 percent of patients with sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Neurosarcoidosis is a diagnostic consideration in patients with known sarcoidosis who develop neurologic complaints and in patients presenting de novo with a constellation of findings consistent with the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Approximately 50 percent of patients with neurosarcoidosis present with neurologic difficulties at the time sarcoidosis is first diagnosed. One-third of those with neurosarcoidosis have or develop more than one neurologic manifestation of their disease.",
"   </p>",
"   <p>",
"    The diagnosis and management of neurosarcoidosis will be reviewed here. General issues related to sarcoidosis and its pathogenesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any portion of the central or peripheral nervous system can be affected by sarcoidosis. Common syndromes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cranial mononeuropathy. Peripheral facial nerve palsy develops in 25 to 50 percent of patients with neurosarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/2,6,7\">",
"       2,6,7",
"      </a>",
"      ]. The facial nerve palsy can be unilateral or bilateral (simultaneous or sequential) and recurrent. Optic neuropathy and cranial nerve VIII dysfunction can lead to intermittent or progressive visual, auditory, or vestibular dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link&amp;anchor=H12#H12\">",
"       \"Optic neuropathies\", section on 'Sarcoidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuroendocrine dysfunction typically occurs with hypothalamic inflammation, resulting in polyuria or disturbances in thirst, sleep, appetite, temperature, or libido. Hypothalamic or pituitary lesions may also cause thyroid, gonadal, or adrenal abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6,8\">",
"       6,8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=see_link\">",
"       \"Causes of hypopituitarism\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      One such manifestation, polyuria, can result from one or more factors in patients with sarcoidosis. Direct hypothalamic involvement can lead to central diabetes insipidus or primary polydipsia, while hypercalcemia (due to production of calcitriol by activated macrophages) can cause nephrogenic diabetes insipidus [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"       \"Hypercalcemia in granulomatous diseases\"",
"      </a>",
"      .) Thus, all patients with sarcoidosis and polyuria require a water restriction test to establish the correct diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"       \"Diagnosis of polyuria and diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Granulomatous inflammation in a perivascular distribution can involve the brain and produce partial or generalized seizures, or a restricted or generalized",
"      <span class=\"nowrap\">",
"       encephalopathy/vasculopathy",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Patients can present with cognitive or behavioral problems",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      focal neurologic deficits referable to the anatomic area involved. In rare cases, this manifests as a focal cerebral infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A myelopathy or radiculopathy can occur if granulomatous inflammation affects the spinal cord [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6,7,11,12\">",
"       6,7,11,12",
"      </a>",
"      ]. The lesions are typically perivascular, they can be extramedullary or intramedullary, and can involve the cauda equina.",
"     </li>",
"     <li>",
"      Communicating or noncommunicating hydrocephalus may develop acutely or subacutely. Asymptomatic ventricular enlargement may be incidentally detected by imaging studies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/13\">",
"       13",
"      </a>",
"      ]. Sudden death can rarely result from acute obstruction to CSF flow.",
"     </li>",
"     <li>",
"      Meningeal involvement can take the form of either an acute aseptic meningitis or a chronic meningitis. Meningeal mass lesions also can develop.",
"     </li>",
"     <li>",
"      Peripheral neuropathic presentations include a mononeuropathy, mononeuritis multiplex, and generalized sensory, small fiber sensory, sensorimotor, autonomic and motor polyneuropathies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/14\">",
"       14",
"      </a>",
"      ]. The symptoms can be acute, subacute, or chronic; electromyography usually reveals an axonal neuropathy. In addition, an acute generalized demyelinating motor neuropathy similar to the Guillain-Barr&eacute; syndrome also has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"       \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carpal tunnel syndrome appears to be more common among patients with sarcoidosis than the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/16-18\">",
"       16-18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23911?source=see_link\">",
"       \"Etiology of carpal tunnel syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Muscle involvement includes asymptomatic microscopic nodules, isolated palpable nodules, an acute or chronic proximal myopathy, and muscle atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients presenting with neurosarcoidosis may have no systemic features of the disease. In one case series, non-neurologic symptoms were present in less than one-fourth of patients and were most commonly anterior uveitis, cough and dyspnea, renal impairment, rash, and polyarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurosarcoidosis is a diagnostic consideration in patients with known sarcoidosis who develop neurologic findings, although an intercurrent infection or malignancy must be excluded. Patients who develop a neurologic illness consistent with neurosarcoidosis but are not known to have sarcoidosis present a diagnostic challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time course and details of presentation sometimes assist in differentiating neurosarcoidosis from other diseases, but many illnesses can present in a manner indistinguishable from neurosarcoidosis. Some representative situations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cranial nerve dysfunction &mdash; A patient with a peripheral facial nerve palsy may have an idiopathic Bell's palsy or a facial neuropathy associated with Lyme disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations of Lyme disease in adults\", section on 'Neurologic manifestations'",
"      </a>",
"      .) An optic neuropathy may be indistinguishable from a multiple sclerosis-associated optic neuritis. Chronic infections, such as tuberculosis, and carcinomatous or lymphomatous meningitis should be considered in patients with multiple cranial nerve palsies.",
"     </li>",
"     <li>",
"      Parenchymal lesions &mdash; Parenchymal granulomatous masses can masquerade as an astrocytoma or other primary or metastatic brain tumors. Multiple small white matter areas of increased T2 signal on magnetic resonance imaging (MRI) are a nonspecific finding and can be associated with multiple sclerosis or other inflammatory disorders.",
"     </li>",
"     <li>",
"      Encephalopathy &mdash; The",
"      <span class=\"nowrap\">",
"       encephalopathy/vasculopathy",
"      </span>",
"      of sarcoidosis can be difficult to distinguish from syphilis or CNS vasculitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=see_link\">",
"       \"Primary angiitis of the central nervous system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meningeal disease &mdash; Sarcoidosis-associated aseptic meningitis is indistinguishable from that caused by viral infections, including HIV, or by tuberculosis or syphilis. A granulomatous meningeal mass may look like a meningioma on imaging studies.",
"     </li>",
"     <li>",
"      Peripheral neuropathy &mdash; Other causes of neuropathy need to be considered depending upon the type of neuropathy present. Acquired etiologies of neuropathy include toxin exposure, metabolic abnormalities, and inflammatory disorders.",
"     </li>",
"     <li>",
"      Muscle weakness &mdash; Polymyositis and other causes of acquired muscle weakness need to be considered if a myopathic process is identified. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"       \"Approach to the patient with muscle weakness\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the passage of time and with observation of the clinical course, some diagnostic considerations become more or less tenable. As an example, an immunosuppressed patient who remains relatively well over one to two years is unlikely to be suffering from an infection or malignancy. If deterioration occurs in conjunction with corticosteroid therapy, complications of chronic corticosteroid use, such as steroid-induced diabetes mellitus, myopathy, or epidural lipomatosis may be contributing to the patient's decline. Opportunistic infections, such as cryptococcal meningitis or progressive multifocal leukoencephalopathy, can also occur in the immunosuppressed individual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"    </a>",
"    .) If deterioration in disease occurs after a period of clinical stability, an intercurrent problem should be considered initially, rather than an exacerbation of sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If neurosarcoidosis is suspected, the patient should be evaluated for evidence of extraneural disease because obtaining nerve tissue for diagnostic evaluation is often difficult. Corticosteroids can eliminate evidence of systemic inflammation, and the diagnostic evaluation should be pursued in a rapid fashion while withholding immunosuppressive therapy unless severe illness mandates its use.",
"   </p>",
"   <p>",
"    The search for extraneural sarcoidosis should include a thorough evaluation of the skin, lymph nodes, and lungs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .) Other tests that may be useful are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ophthalmologic examination",
"     </li>",
"     <li>",
"      Endoscopic nasal and sinus examination",
"     </li>",
"     <li>",
"      A chest x-ray or computed tomographic scan of the chest to look for hilar adenopathy or parenchymal changes consistent with pulmonary sarcoidosis. Positive findings suggestive of sarcoidosis on chest imaging have been reported in 24 to 68 percent of individuals who present with neurologic sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum angiotensin converting enzyme (ACE) assay, which may be helpful if elevated; however, an elevated serum ACE is not specific for sarcoidosis, and the ACE concentration may not necessarily be elevated if the patient has isolated neurosarcoidosis",
"     </li>",
"     <li>",
"      In occasional cases, a magnetic resonance, gallium, or fluorodeoxyglucose positron emission tomographic scan, may highlight otherwise occult areas of inflammation that might be amenable to biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurodiagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic evaluation should proceed if no extraneural tissue is available for biopsy. Unfortunately,",
"    <strong>",
"     no",
"    </strong>",
"    neurodiagnostic tests are pathognomonic for neurosarcoidosis. However, neurodiagnostic tests help define the extent of disease and eliminate other diagnostic considerations, particularly infection and malignancy. Furthermore, a presumptive diagnosis of neurosarcoidosis is often made on the basis of MRI and lumbar puncture results in the appropriate clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The imaging procedure of choice for CNS disease is contrast-enhanced MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/7,8,21\">",
"     7,8,21",
"    </a>",
"    ]. Meningeal or parenchymal enhancement suggests active inflammation with disruption of the blood brain barrier, and parenchymal or meningeal masses and hydrocephalus are easily identified. Involvement of the optic nerve or other cranial nerves can be documented, and spinal cord and cauda equina inflammation is well seen on targeted images. Multiple parenchymal nodules may actually represent inflammation extending along the Virchow-Robin spaces deep into the brain or spinal cord. In one series of 29 patients with neurosarcoidosis, approximately 40 percent demonstrated meningeal enhancement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiple white matter lesions on MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrospinal fluid (CSF) abnormalities occur frequently in patients with CNS sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CSF opening pressure is elevated in approximately 10 percent of patients, and the total protein is increased in two-thirds of patients, typically up to 250",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      A pleocytosis is present in approximately 50 percent of patients",
"     </li>",
"     <li>",
"      Glucose can be normal or low, as can be seen in CNS infections or carcinomatous meningitis",
"     </li>",
"     <li>",
"      A predominantly mononuclear cell pleocytosis is common",
"     </li>",
"     <li>",
"      The IgG index can be elevated, and oligoclonal bands may be present",
"     </li>",
"     <li>",
"      The CSF ACE concentration is occasionally elevated, but reliable normal values are lacking and CSF ACE may also be increased with infection or carcinomatous meningitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Caution should be applied in performing a LP in patients with neurosarcoidosis if there is evidence of increased intracranial pressure. A funduscopic examination to exclude papilledema and an MRI to exclude ventricular enlargement, cerebral edema, and a mass lesion should precede LP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other diagnostic tests, such as electroencephalography, evoked potentials, and angiography, are occasionally indicated to exclude other conditions. Nerve conduction studies (NCS) and electromyography (EMG) can help localize neuromuscular lesions, depending on the clinical syndrome.",
"   </p>",
"   <p>",
"    Although false-positive reactions to the Kveim-Siltzbach test are reported to be rare; the test has limited utility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6\">",
"     6",
"    </a>",
"    ]. The test is not standardized; it is not universally available; and there are concerns regarding the transmission of HIV and hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"     \"Pathogenesis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the diagnosis remains in doubt, meningeal, brain, or spinal cord biopsy is occasionally indicated. Extraneural tissue biopsy from other clinically affected organs is generally preferable when possible, as it is less risky; skin, lymph node, and lung (transbronchial) biopsies can be of high yield [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Muscle and peripheral nerve biopsy, including an epidermal biopsy with quantitative nerve terminal analysis to document small fiber sensory neuropathy, can all be easily performed for the appropriate syndrome.",
"   </p>",
"   <p>",
"    Biopsy to establish the diagnosis, rather than empiric therapy, should be considered if there is no defined systemic disease (see below). Biopsy, in an attempt to uncover an alternative neurologic diagnosis, should also be considered for patients with known systemic sarcoidosis and neurologic disease who are progressively deteriorating despite therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized, double blind, placebo-controlled treatment trials for neurosarcoidosis, but there is a consensus that these patients should be treated with corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/24\">",
"     24",
"    </a>",
"    ]. Treatment strategies with alternative agents have also been proposed (",
"    <a class=\"graphic graphic_algorithm graphicRef58324 \" href=\"UTD.htm?8/6/8303\">",
"     algorithm 1",
"    </a>",
"    ). Sarcoidosis is a systemic disease, and treatment should address the burden of disease in all involved organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids are the first line agents for the treatment of neurosarcoidosis, and the dose and duration of therapy should be dictated by disease severity and response to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    .) Different regimens are generally utilized depending upon the site of neurologic involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a peripheral facial nerve palsy or aseptic meningitis are often treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for two weeks, and for a slightly longer duration by some physicians",
"     </li>",
"     <li>",
"      Patients with a myopathy or neuropathy are usually treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for four weeks and their response assessed",
"     </li>",
"     <li>",
"      A meningeal or parenchymal mass lesion,",
"      <span class=\"nowrap\">",
"       encephalopathy/vasculopathy,",
"      </span>",
"      or symptomatic hydrocephalus often requires",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1.0 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for four weeks before any benefit is appreciated",
"     </li>",
"     <li>",
"      Severely incapacitated or rapidly deteriorating patients may respond to intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for three days followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1.0 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for two to four weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A slow",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper should be considered in patients who are severely compromised or for whom a chronic course is likely. One useful approach is to allow the patient to stabilize or improve with four weeks of treatment and then to decrease the prednisone dose by 5 mg every two weeks as tolerated by symptoms. Exacerbations are most common when a prednisone dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is approached; thus, the dose should be decreased by 1 mg decrements every one to two weeks when the dose is near this level.",
"   </p>",
"   <p>",
"    Acute deterioration is unusual if corticosteroids are tapered in this fashion and patients are closely monitored. If the patient's symptoms recur, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose should be doubled if the deterioration occurred at a dose of prednisone above 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    or increased to 10 to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    if a relapse occurred at lower doses.",
"   </p>",
"   <p>",
"    Frequent clinical evaluation and periodic assessment of the extent of MRI enhancement (if enhancement was present on pretreatment scans) are generally helpful as corticosteroids are weaned; monitoring of nerve conduction velocities and the electromyogram is occasionally useful. In contrast, titrating therapy to normalize CSF parameters is",
"    <strong>",
"     not",
"    </strong>",
"    recommended because excessive immunosuppression frequently results from this practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other immunomodulatory therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who deteriorate in spite of aggressive corticosteroid treatment, who cannot tolerate corticosteroids, or who have a primary contraindication to corticosteroid treatment may benefit from alternative therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. There have been no studies comparing various alternative treatments to one another in patients with neurosarcoidosis. A decision about the specific agent should be based upon ease of use, cost, and the desire to avoid the complications of a particular drug. There is little rigorous evidence that use of an alternative agent will result in a better functional clinical outcome than \"optimal\" corticosteroid therapy, although 10 to 30 percent of patients improve to a greater extent than with corticosteroid monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Many patients treated with alternative agents respond most favorably if they are maintained on a modest corticosteroid regimen (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    10 to 20",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , and the purine analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    (2-chlorodeoxyadenosine) are immunosuppressive agents that have been used with limited success to treat neurosarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6,26-31\">",
"     6,26-31",
"    </a>",
"    ]. In one small case series, mycophenolate mofetil was effective for treating disease affecting the central nervous system but not sarcoid myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/32\">",
"     32",
"    </a>",
"    ]. The actual target blood level of cyclosporine needs to be defined according to the specific assay used. It is reasonable to achieve a blood level comparable to that used for renal transplant recipients. Dosing of azathioprine, chlorambucil, and cyclophosphamide should be targeted to achieve hematologic endpoints. We recommend lowering the total white blood cell count to approximately 3500 or the lymphocyte count to 1000 per mm3. Patient response to any specific drug cannot be predicted, and one should try two or three agents before concluding that the patient's disease is refractory.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    (Remicade) is a chimeric human-murine antihuman antibody that specifically blocks the effect of tumor necrosis factor-alpha (TNF-alpha). Preliminary results indicate that infliximab may be useful in selected patients with pulmonary and extrapulmonary sarcoidosis refractory to corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/33-38\">",
"     33-38",
"    </a>",
"    ]. In one series of seven patients with corticosteroid-refractory neurosarcoidosis, treatment with infliximab (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil in six patients) was associated with symptom relief, regression of neurologic deficits, and a decrease in disease activity on MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/39\">",
"     39",
"    </a>",
"    ]. Another series reported stabilization and improvement in four patients with central nervous system manifestations of neurosarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/40\">",
"     40",
"    </a>",
"    ]. A single case report describes the successful use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (monoclonal antibody directed against B cells) in a patient with CNS neurosarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/41\">",
"     41",
"    </a>",
"    ]Use of infliximab requires an intravenous infusion (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of ideal body weight) initially, and periodically thereafter as the clinical course is monitored. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other immunomodulatory agents used in the management of neurosarcoidosis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/42\">",
"     42",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. These drugs are occasionally used in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    as steroid sparing agents or as adjunctive therapy with high-dose prednisone in patients refractory to treatment with glucocorticoids alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of a CNS mass lesion is rarely indicated, and patients may deteriorate following attempted resection of a mass. If biopsy of a mass lesion is consistent with sarcoidosis, resection usually should be deferred while appropriate medical management is pursued. If a mass lesion persists or enlarges despite \"optimal\" immunosuppressive therapy, resection may need to be considered.",
"   </p>",
"   <p>",
"    A ventricular drain can be life saving in patients with acute hydrocephalus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6\">",
"     6",
"    </a>",
"    ]. Placement of a ventriculoperitoneal shunt is indicated for symptomatic hydrocephalus despite the fact that the presence of a foreign object in an immunocompromised patient predisposes to infection. Immunosuppressive therapy should continue immediately following shunt placement to treat the underlying inflammatory process. Inflammation due to neurosarcoidosis often leads to shunt obstruction, necessitating multiple shunt revisions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial or spinal irradiation has been used for refractory disease and should be considered if patients fail corticosteroid therapy and trials of at least two alternative agents [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/48\">",
"     48",
"    </a>",
"    ]. The modality has also occasionally been required for patients with acute, life-threatening disease. Immunosuppression is generally continued during radiation therapy, albeit at less intense levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrinologic deficiencies should be corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/8\">",
"     8",
"    </a>",
"    ]. Hypothalamic hypothyroidism should be excluded if a patient has CNS disease beyond a single cranial nerve deficit. This requires measurement of the T4 concentration, since serum thyrotropin (TSH) concentrations may be normal or low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    .) Testosterone deficiency is often clinically silent and should be sought in patients with symptoms or other signs of hypothalamic or pituitary disease. Treatment of an otherwise occult testosterone deficiency may help preserve muscle and bone mass.",
"   </p>",
"   <p>",
"    Patients who require prolonged corticosteroid therapy may benefit from early dietary counseling and an exercise program to mitigate weight gain and debilitation. Intervention to prevent excessive bone loss is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with neurosarcoidosis can have a monophasic illness (approximately two-thirds of patients), a relapsing-remitting course, or progressive disease punctuated by episodic deteriorations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/6,49,50\">",
"     6,49,50",
"    </a>",
"    ]. Historically, approximately 10 percent of patients die as a direct result of the inflammatory process or its treatment. These patients typically have CNS parenchymal disease or hydrocephalus and are often profoundly immunocompromised due to treatment.",
"   </p>",
"   <p>",
"    The long-term course of neurosarcoidosis has not been clearly defined. Nevertheless, some generalizations are possible based upon observations of treated individuals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a peripheral facial nerve palsy tend to improve over two to four weeks. Other lower cranial mononeuropathies follow a similar course [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Optic neuropathy can improve over several weeks, but some patients have a progressive course ending in blindness [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aseptic meningitis usually resolves over several weeks, although an asymptomatic chronic pleocytosis can persist.",
"     </li>",
"     <li>",
"      Meningeal or parenchymal mass lesions often exhibit a prolonged course, although some mass lesions resolve over time.",
"     </li>",
"     <li>",
"      Endocrinopathies rarely improve with immunosuppression; as a result, chronic hormonal replacement therapy is usually necessary.",
"     </li>",
"     <li>",
"      Hypothalamic vegetative symptoms can respond to treatment but rarely resolve spontaneously.",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       encephalopathy/vasculopathy",
"      </span>",
"      of sarcoidosis is typically progressive albeit with periods of improvement and deterioration.",
"     </li>",
"     <li>",
"      Seizure control is usually not difficult as long as the underlying inflammatory process is controlled [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20616/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ventricular enlargement can be asymptomatic or can cause acute or chronic deterioration.",
"     </li>",
"     <li>",
"      Peripheral neuropathic and myopathic illness tends to be chronic and progressive, although remissions are possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7966393\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic complications potentially affecting any portion of the central or peripheral nervous system occur in approximately 5 percent of patients with sarcoidosis and can be the presenting feature. Common syndromes include a cranial mononeuropathy, neuroendocrine dysfunction, a focal or multifocal encephalopathy, myelopathy, hydrocephalus, aseptic meningitis, peripheral neuropathy or myopathy (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Diagnostic evaluation requires distinguishing neurosarcoidosis from a variety of other inflammatory and infectious conditions (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      A thorough evaluation for systemic sarcoidosis (eg, chest imaging) can expedite the evaluation by providing tissue that is accessible for biopsy. In the absence of systemic sarcoidosis, testing that may be helpful includes magnetic resonance imaging of the affected area, cerebrospinal fluid evaluation (with expected findings described above) and serum angiotensin converting enzyme level. None of these tests have perfect sensitivity and specificity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Neurodiagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsy should be considered in all patients in whom diagnosis remains in doubt, as treatment is prolonged and associated with complications (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Biopsy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest corticosteroid therapy as the first treatment in a patient with neurosarcoidosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The dose and duration are determined by the severity of the illness and treatment response, with some suggested guidelines outlined above (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Corticosteroids'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients who deteriorate in spite of aggressive corticosteroid treatment, who cannot tolerate corticosteroids, or who have a primary contraindication to corticosteroid treatment may benefit from alternative therapies. Benefits have been observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Other immunomodulatory therapies'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      Radiation can be attempted in patients with CNS disease refractory to medical treatment (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Radiation therapy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Patients with neurosarcoidosis can have a monophasic illness (approximately two-thirds of patients), a relapsing-remitting course, or progressive disease punctuated by episodic deteriorations (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Prognosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/1\">",
"      Burns TM. Neurosarcoidosis. Arch Neurol 2003; 60:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/2\">",
"      Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/3\">",
"      Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol 2007; 7:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/4\">",
"      Terushkin V, Stern BJ, Judson MA, et al. Neurosarcoidosis: presentations and management. Neurologist 2010; 16:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/5\">",
"      Scott TF. Neurosarcoidosis: progress and clinical aspects. Neurology 1993; 43:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/6\">",
"      Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry 2009; 80:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/7\">",
"      Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/8\">",
"      Bihan H, Christozova V, Dumas JL, et al. Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine (Baltimore) 2007; 86:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/9\">",
"      Stuart CA, Neelon FA, Lebovitz HE. Disordered control of thirst in hypothalamic-pituitary sarcoidosis. N Engl J Med 1980; 303:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/10\">",
"      Navi BB, DeAngelis LM. Sarcoidosis presenting as brainstem ischemic stroke. Neurology 2009; 72:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/11\">",
"      Junger SS, Stern BJ, Levine SR, et al. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology 1993; 43:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/12\">",
"      Reda HM, Taylor SW, Klein CJ, Boes CJ. A case of sensory ataxia as the presenting manifestation of neurosarcoidosis. Muscle Nerve 2011; 43:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/13\">",
"      Brouwer MC, de Gans J, Willemse RB, van de Beek D. Neurological picture. Sarcoidosis presenting with hydrocephalus. J Neurol Neurosurg Psychiatry 2009; 80:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/14\">",
"      Zuniga G, Ropper AH, Frank J. Sarcoid peripheral neuropathy. Neurology 1991; 41:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/15\">",
"      Saifee TA, Reilly MM, Ako E, et al. Sarcoidosis presenting as acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2011; 43:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/16\">",
"      Niemer GW, Bolster MB, Buxbaum L, Judson MA. Carpal tunnel syndrome in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/17\">",
"      Nakatani-Enomoto S, Aizawa H, Koyama S, et al. Transient swelling of peripheral nerves in a case of neurosarcoidosis. Intern Med 2004; 43:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/18\">",
"      SHAMBAUGH GE, CIRKSENA WJ, NEWCOMER KL. CARPAL TUNNEL SYNDROME AS MANIFESTATION OF SARCOIDOSIS. Arch Intern Med 1964; 114:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/19\">",
"      Ando DG, Lynch JP 3rd, Fantone JC 3rd. Sarcoid myopathy with elevated creatine phosphokinase. Am Rev Respir Dis 1985; 131:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/20\">",
"      Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis--diagnosis and management. QJM 1999; 92:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/21\">",
"      Sherman JL, Stern BJ. Sarcoidosis of the CNS: comparison of unenhanced and enhanced MR images. AJNR Am J Neuroradiol 1990; 11:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/22\">",
"      Scott TF. Cerebral herniation after lumbar puncture in sarcoid meningitis. Clin Neurol Neurosurg 2000; 102:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/23\">",
"      Peeples DM, Stern BJ, Jiji V, Sahni KS. Germ cell tumors masquerading as central nervous system sarcoidosis. Arch Neurol 1991; 48:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/24\">",
"      Stern BJ, Corbett J. Neuro-ophthalmologic Manifestations of Sarcoidosis. Curr Treat Options Neurol 2007; 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/25\">",
"      Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995; 52:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/26\">",
"      Scott TF, Yandora K, Valeri A, et al. Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients. Arch Neurol 2007; 64:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/27\">",
"      Stern BJ, Schonfeld SA, Sewell C, et al. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol 1992; 49:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/28\">",
"      Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 1997; 112:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/29\">",
"      Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/30\">",
"      Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003; 124:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/31\">",
"      Tikoo RK, Kupersmith MJ, Finlay JL. Treatment of refractory neurosarcoidosis with cladribine. N Engl J Med 2004; 350:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/32\">",
"      Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011; 76:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/33\">",
"      Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004; 63:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/34\">",
"      Morcos Z. Refractory neurosarcoidosis responding to infliximab. Neurology 2003; 60:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/35\">",
"      Katz JM, Bruno MK, Winterkorn JM, Nealon N. The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 2003; 60:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/36\">",
"      Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/37\">",
"      Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004; 117:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/38\">",
"      Hoitsma E, Faber CG, van Santen-Hoeufft M, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/39\">",
"      Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 2009; 72:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/40\">",
"      Santos E, Shaunak S, Renowden S, Scolding NJ. Treatment of refractory neurosarcoidosis with Infliximab. J Neurol Neurosurg Psychiatry 2010; 81:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/41\">",
"      Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/42\">",
"      Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol 1998; 55:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/43\">",
"      Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/44\">",
"      Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999; 159:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/45\">",
"      Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/46\">",
"      Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998; 39:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/47\">",
"      Rousseau L, Beylot-Barry M, Doutre MS, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol 1998; 134:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/48\">",
"      Menninger MD, Amdur RJ, Marcus RB Jr. Role of radiotherapy in the treatment of neurosarcoidosis. Am J Clin Oncol 2003; 26:e115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/49\">",
"      Luke RA, Stern BJ, Krumholz A, Johns CJ. Neurosarcoidosis: the long-term clinical course. Neurology 1987; 37:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/50\">",
"      Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20616/abstract/51\">",
"      Krumholz A, Stern BJ, Stern EG. Clinical implications of seizures in neurosarcoidosis. Arch Neurol 1991; 48:842.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4834 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-37932DBF7B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20616=[""].join("\n");
var outline_f20_8_20616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7966393\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurodiagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other immunomodulatory therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgical considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7966393\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4834\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4834|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/6/8303\" title=\"algorithm 1\">",
"      Treatment of neurosarcoidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35225?source=related_link\">",
"      Clinical manifestations of Lyme disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23911?source=related_link\">",
"      Etiology of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=related_link\">",
"      Optic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=related_link\">",
"      Pathogenesis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_8_20617="Role of echocardiography in infective endocarditis";
var content_f20_8_20617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of echocardiography in infective endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20617/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20617/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20617/contributors\">",
"     Bryan Ristow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20617/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20617/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20617/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20617/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20617/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/8/20617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the endocardium or lining layer of the heart can occur on valve leaflets, congenital defects, the walls or chordae of the chambers, paraprosthetic tissue, or the attachment of implanted shunts, conduits, and fistulae. The clinical diagnosis of infective endocarditis (IE) is based upon a combination of features such as positive blood cultures, new valvular regurgitation, and fever (",
"    <a class=\"graphic graphic_table graphicRef73023 graphicRef53004 \" href=\"UTD.htm?42/47/43773\">",
"     table 1A-B",
"    </a>",
"    ) as specified in the modified Duke criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The original case definition of endocarditis required direct anatomic inspection (autopsy or at surgery) for confirmation of diagnosis. While no noninvasive technique can definitively establish the diagnosis, echocardiography, because of its high sensitivity for valvular vegetations and complications of IE, is considered mandatory in the clinical diagnosis and treatment of this disorder. The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines for valvular heart disease include recommendations for echocardiography in both native valve and prosthetic valve endocarditis (",
"    <a class=\"graphic graphic_table graphicRef60777 \" href=\"UTD.htm?32/34/33324\">",
"     table 2",
"    </a>",
"    ) and have adopted the modified Duke criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of echocardiography in IE will be reviewed here, with emphasis on the clinical issues of its application and its potential weaknesses and pitfalls. The clinical diagnostic approach to this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF INFECTIVE ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modified Duke criteria for diagnosis of infective endocarditis include three echocardiographic structural findings as major criteria: presence of an oscillating intracardiac mass, presence of an abscess, or partial dehiscence of a prosthetic valve (",
"    <a class=\"graphic graphic_table graphicRef73023 graphicRef53004 \" href=\"UTD.htm?42/47/43773\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/1\">",
"     1",
"    </a>",
"    ]. New valvular regurgitation is also a major criterion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VALVULAR VEGETATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first target of the echocardiography examination is the identification, characterization, and localization of masses consistent with valvular vegetation, the pathologic hallmark of endocarditis. This process consists of integrating circumstantial findings and epiphenomena, and, through indirect but compelling evidence, reaching a reasonable conclusion that a given set of echocardiographic observations has identified the vegetation. Once a vegetation has been identified, a series of criteria can be applied to judge prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Procedural considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Equipment, patient characteristics, and the pretest level of suspicion for endocarditis all influence the diagnostic value of the echocardiographic findings in a patient with suspected infective endocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Transducer frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower frequency transducers, ie, nominal center line frequency of approximately 2.5 to 4.0 mHz, are most commonly employed in adults because they combine superior penetration with optimal color flow and spectral Doppler sensitivity. However, the images are lower in resolution than those obtained at higher frequencies (eg, 5.0 to 6.0 mHz), particularly in the middle and far fields of the image where beam spread results in image degradation.",
"   </p>",
"   <p>",
"    The mitral valve lies in the middle field (precordial window) and far field (apical) and, even when normal, tends to take on an irregular or lumpy appearance when imaged with lower frequencies. If small vegetations are present, they tend to be obscured and normal irregularities magnified. For these reasons, both lower frequency and higher frequency transducers should be used for routine examinations in order to develop familiarity with the normal appearance of cardiac structures generated under both circumstances, and to promote recognition of genuine pathologic changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Commercial instrument and instrument setting variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dynamic range options, pre- and post-processing algorithms among instruments, and changes in these settings within instruments alter the appearance of valves. Depth settings, probe frequency, deployment of electronic focusing, and sector width have differing influences on the frame rate at which the image is displayed. Variable focus, high frame rate, and zoom settings are helpful. At larger depth settings, such as 20 cm, slower frame rates may obscure the characteristic rapid vibrations of many vegetations.",
"   </p>",
"   <p>",
"    Some devices offer \"B color\" tagging of tissue images that extend the dynamic range of a gray scale image and can influence the appearance of valve pathology. The highly reflective nature of calcific degeneration may be easier to differentiate from the tissue or thrombus-like appearance of vegetations when using this type of image processing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Patient physical characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transmission of ultrasound between the transducer and the heart is impeded by obesity, hyperinflated lungs during mechanical ventilation, narrow interspaces,",
"    <span class=\"nowrap\">",
"     valve/annular",
"    </span>",
"    calcification, and valve prostheses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"     \"Examination of the precordial pulsation\"",
"    </a>",
"    .) All of these factors may obscure vegetations.",
"   </p>",
"   <p>",
"    Transesophageal echocardiography (TEE) is less susceptible to these constraints and usually provides excellent image quality. However, TEE is not impervious to technical limitations. For example, it is often necessary to remove a nasogastric feeding tube for ideal imaging. Differences between transthoracic echocardiography (TTE) and TEE must be considered when analyzing the endocarditis literature and choosing the best imaging modality for a given patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pretest expectations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician or sonographer should begin each examination, or its interpretation, with some notion about what is being sought. If there is strong suspicion of endocarditis, it is only natural to expand the scrutiny of the valves with extra images using a complete array of probes and processing algorithms. Under such circumstances, maximal \"performance\" of the technique may be approached. However, as sensitivity rises, specificity falls, particularly under the magnification of increased surveillance. Every normal study contains small, normally unseen irregularities (eg, Lambl's excrescences), processes, and artifacts that are easily misinterpreted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     M-mode echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;M-mode echocardiography was the first ultrasound imaging modality widely applied in endocarditis, and the lower limit of detecting valve vegetations was estimated at 5 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/4\">",
"     4",
"    </a>",
"    ]. While its role has diminished with the advent of two-dimensional echocardiography, it may still provide important information (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56693 \" href=\"UTD.htm?35/45/36566\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    M-mode recordings offer very high sampling rates (&gt;1000 Hz compared with 30 to 60 Hz for two-dimensional echocardiography). On the M-mode echocardiogram, vegetations appear as echogenic, shaggy masses on one of the valve leaflets. M-mode echocardiography can easily recognize vegetations that prolapse (by location), and can detect their characteristic tissue level images and vibrations.",
"   </p>",
"   <p>",
"    While it is normal for the aortic valve to vibrate slightly during systole, diastolic vibrations almost certainly identify a mass as a vegetation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a torn leaflet. Similarly, systolic mitral vibrations are highly suspicious of a vegetation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ruptured valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Transthoracic echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of two-dimensional transthoracic echocardiography (TTE) for detecting vegetations in IE has been evaluated in a variety of studies (",
"    <a class=\"graphic graphic_movie graphicRef73652 \" href=\"UTD.htm?22/46/23279\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef52651 \" href=\"UTD.htm?30/9/30867\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef55154 \" href=\"UTD.htm?21/47/22260\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef79209 \" href=\"UTD.htm?21/28/21954\">",
"     movie 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef70221 \" href=\"UTD.htm?0/29/466\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62352 graphicRef53904 \" href=\"UTD.htm?0/13/215\">",
"     image 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66283 \" href=\"UTD.htm?25/2/25635\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a meta-analysis of 16 early reports involving 641 patients, TTE had a mean sensitivity of 79 percent for the detection of vegetations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/5\">",
"     5",
"    </a>",
"    ]. There is generally good agreement between the location and identity of large vegetations on TTE and pathologic findings from autopsy or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/6\">",
"     6",
"    </a>",
"    ]. However, there are limitations to comparison of ultrasound measurements to pathologic findings and small vegetations of less than 3 mm may be undetectable by TTE [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported sensitivity of TTE in IE decreased in later reports despite major improvements in ultrasound equipment. A review of seven studies performed between 1989 and 1994 found that the mean sensitivity for TTE was 62 percent, much lower than the initially reported value of 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. This unexpected drop in TTE sensitivity is probably due to a combination of more rigorous and less biased case selection and less intense scrutiny of the patient with TTE than with the newer technique, TEE.",
"   </p>",
"   <p>",
"    The measurements of structures in echocardiographic studies are limited by image resolution. TTE underestimates the size and complexity of large vegetations and fails to detect small vegetations (&lt;3 mm in diameter). If the precise size and behavior of vegetations has prognostic and therapeutic significance, it is reasonable to anticipate that TTE will underachieve as a prognostic and therapeutic guide. Furthermore, there is considerable variation in performance of transthoracic echocardiography within and among studies, further weakening the application of reported results into clinical practice. However continuing technical improvements in transthoracic imaging may narrow differences between transthoracic and transesophageal image quality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Transesophageal echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of the more invasive and expensive transesophageal echocardiogram (TEE) in the diagnosis of IE stems from its high sensitivity in detecting and defining valve vegetations (",
"    <a class=\"graphic graphic_movie graphicRef65848 \" href=\"UTD.htm?29/38/30306\">",
"     movie 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef58456 \" href=\"UTD.htm?17/39/18035\">",
"     movie 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef81420 \" href=\"UTD.htm?12/53/13151\">",
"     movie 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef58762 \" href=\"UTD.htm?40/16/41230\">",
"     movie 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef74517 \" href=\"UTD.htm?25/30/26082\">",
"     movie 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76481 graphicRef65378 graphicRef74507 \" href=\"UTD.htm?42/0/43015\">",
"     image 4A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The sensitivity of TEE is substantially higher than the values achieved with the transthoracic approach (92 versus 62 percent in the seven studies mentioned above) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. A similar difference was noted in five studies that compared the sensitivity of the two methods for detecting definite vegetations as defined below (93 versus 46 percent); the specificity was not different (96 versus 95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/7,11,13-15\">",
"     7,11,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of valvular heart disease included recommendations on the role of TTE and TEE in IE (",
"    <a class=\"graphic graphic_table graphicRef60777 \" href=\"UTD.htm?32/34/33324\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/2\">",
"     2",
"    </a>",
"    ]. The main use for TEE was when TTE was nondiagnostic. The only indication for TEE as a first-line test was to diagnose prosthetic valve endocarditis and assess for complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     False positive results",
"    </span>",
"    &nbsp;&mdash;&nbsp;False positives in TEE arise because small, previously invisible irregularities and degenerative processes are clearly seen in magnified format [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tiny mobile strands are frequently encountered on the valves; these strands probably represent a normal degenerative process and are known as Lambl's excrescences.",
"     </li>",
"     <li>",
"      Strands, possibly from the same source, can also arise on the sewing ring of prosthetic valves. In addition, a free suture end can occasionally be visualized and may be mistaken for a pathologic finding.",
"     </li>",
"     <li>",
"      Redundant chordae or false tendons in the left ventricle as well as Chiari's remnant in the right atrium may be mistaken for vegetative masses.",
"     </li>",
"     <li>",
"      Chordal insertion into normal mitral valve margins may mimic a mass.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these masses have in common a tendency to be highly reflective in appearance with the approximate echodensity of pericardium or aortic root. Their dense fibrotic nature can best be appreciated by noting their bright nonvibratory nature on M-mode imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     False negative results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implications of an initial TEE examination that fails to show vegetations in a patient with suspected IE should be carefully considered. The sensitivity of TEE has been reported as 92 to 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/7,11,13-15\">",
"     7,11,13-15",
"    </a>",
"    ]. Although TEE cannot definitively rule out endocarditis, its high diagnostic sensitivity results in a low probability of the disease when negative results are obtained in a patient with an intermediate likelihood of the disease.",
"   </p>",
"   <p>",
"    However, repeat examination is important, particularly in patients at high risk for IE, such as those with a prosthetic valve or unexplained bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/13\">",
"     13",
"    </a>",
"    ]. Although the rate of false negative TEE examinations in patients with IE is low, negative results confer an obligation of careful follow-up with exercise of sound clinical judgment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnostic criteria for vegetations",
"    </span>",
"    &nbsp;&mdash;&nbsp;With either transthoracic or transesophageal methods, a valvular vegetation is defined as \"a discrete mass of echogenic material adherent at some point to a leaflet surface and distinct in character from the remainder of the leaflet\" based upon the following characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Texture &ndash; gray scale and reflectance of myocardium",
"     </li>",
"     <li>",
"      Location &ndash; upstream side of the valve in the path of the jet or on prosthetic material",
"     </li>",
"     <li>",
"      Characteristic motion &ndash; chaotic and orbiting; independent of valve motion",
"     </li>",
"     <li>",
"      Shape &ndash; lobulated and amorphous",
"     </li>",
"     <li>",
"      Accompanying abnormalities &ndash; abscess and pseudoaneurysm, fistulae, prosthetic dehiscence, paravalvular leak, significant preexisting or new regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vegetations also characteristically prolapse into the upstream chamber: mitral vegetations into the atrium in systole and aortic vegetations into the left ventricular outflow tract during diastole. Vegetations tend to flank the regurgitant jet. Intracardiac foreign structures, such as pacemaker leads, must also be interrogated for the presence of a vegetation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristics of a mass not likely to be a vegetation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Texture &ndash; reflectance of calcium or pericardium (appears white)",
"     </li>",
"     <li>",
"      Location &ndash; outflow tract attachment, downstream surface of valve",
"     </li>",
"     <li>",
"      Shape &ndash; stringy or hair-like strands with narrow attachment",
"     </li>",
"     <li>",
"      Lack of accompanying turbulent flow or regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Masses have also been analyzed according to four properties [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Size &ndash; established by the two largest orthogonal diameters",
"     </li>",
"     <li>",
"      Mobility &ndash; defined as: grade 1, fixed; grade 2, fixed base free edge; grade 3, pedunculated; grade 4, prolapsing",
"     </li>",
"     <li>",
"      Density &ndash; defined as: grade 1, calcified; grade 2, partially calcified; grade 3, denser than myocardium but not calcified; grade 4, equivalent to myocardium",
"     </li>",
"     <li>",
"      Extent &ndash; defined as: grade 1, single; grade 2, multiple on a single leaflet; grade 3, multiple leaflets; grade 4, extending to extravalvular structures",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Natural history of vegetations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography has been used to determine the natural history of vegetations. An increase in size suggests active disease and is an ominous sign (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Vegetation size and embolic risk'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. On the other hand, some vegetations persist after bacterial cure has been achieved and remain stable in size for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/21\">",
"     21",
"    </a>",
"    ]. However, chronic lesions are more echogenic than acute vegetations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The organism may be an important determinant of early changes in vegetation size. In one series, Staphylococcus aureus was more common in vegetations that increased in size or were unchanged during four to eight weeks of therapy (44 versus 11 percent in those with a reduction in vegetation size, p&lt;0.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/19\">",
"     19",
"    </a>",
"    ]. In comparison, Streptococcus viridans was more common in vegetations that decreased in size (33 versus 18 percent, p&lt;0.05).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nonbacterial endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of nonbacterial causes of endocarditis that may produce vegetations; as with bacterial endocarditis, these are also best evaluated with TEE. Other etiologies include various types of fungal infections, brucellosis, gonococcus, and noninfectious causes including Libman-Sacks endocarditis, Loffler's endocarditis, granulomatous diseases, and scleroderma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ECHOCARDIOGRAPHIC ESTIMATION OF OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a vegetation is identified, it is important to estimate the risk that the process poses to the patient's recovery or survival and to decide on an appropriate therapeutic plan. Prognostic estimations and decisions can be made by analysis of the clinical and echocardiographic presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/8,19,23,24\">",
"     8,19,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Transthoracic echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study evaluated the prognostic value of vegetation morphology on transthoracic echocardiography in 204 patients with clinical criteria for IE [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/17\">",
"     17",
"    </a>",
"    ]. Clinical complications including drug failure requiring a change in antibiotic therapy, new onset congestive heart failure, embolization, surgery and death were compared with vegetation characteristics. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Diagnostic criteria for vegetations'",
"    </a>",
"    above.) The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall incidence of complications was 55 percent, with equivalent rates for native and prosthetic valves and for clinical endocarditis in nonspecifically thickened valves. The overall complication rates were roughly equivalent for patients with mitral, aortic, tricuspid, and prosthetic valve vegetations, as well as for those with nonspecific valvular changes but no discrete vegetations. However, the distribution of specific complications varied considerably among these groups.",
"     </li>",
"     <li>",
"      Size was the most powerful predictor of complications. The probability of sustaining a complication was 10 percent when vegetations were 6 mm in size, 50 percent for lesions of 11 mm, and almost 100 percent for lesions &ge;16 mm.",
"     </li>",
"     <li>",
"      There were significantly fewer complications in patients without discernible valvular abnormalities (27 percent).",
"     </li>",
"     <li>",
"      Complications tended to be more frequent with higher grades of mobility and lesion extent. In comparison, vegetation consistency did not predict complications except for calcified lesions which were devoid of complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the above variables, a risk score was proposed, calculated as the sum of the scores (grades 1 to 4) for the three characteristics, ie, size, mobility and extent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/17\">",
"     17",
"    </a>",
"    ]. The highest possible score for any valve was 12. A high score was always present in patients with complications, but less than one-half of those with high scores developed a complication. In multivariate analysis, these factors predicted the occurrence of complications with 70 percent sensitivity and 92 percent specificity in mitral valve endocarditis, and with 76 percent sensitivity and 62 percent specificity in aortic valve endocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Transesophageal echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observations made with TTE are not directly applicable to TEE since a given vegetation is likely to appear larger on TEE. Therefore, a higher score by TEE may signify a comparable level of risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Vegetation size and embolic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some data are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], in general larger vegetation size on TEE appears to be predictive of embolic risk. In a study of 105 patients with IE, patients with a vegetation diameter above 10 mm had a significantly higher incidence of embolic events than did those with smaller vegetations (47 versus 19 percent, p&lt;0.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/8\">",
"     8",
"    </a>",
"    ]. This association was particularly strong in patients with mitral valve endocarditis. Vegetation size did not appear to predict other complications such as severe heart failure and death and was not related to the location of endocarditis or type of organism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A series of 211 patients with 28 embolic events found that vegetation size was associated with embolic risk for staphylococcus and mitral valve vegetations, but was not associated with embolic risk for streptococcus or aortic vegetations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vegetation mobility confers incremental risk beyond vegetation size. In a series of 178 patients with definite IE who underwent TEE, the incidence of embolism, as diagnosed by cerebral and thoracoabdominal CT scans, was higher when vegetation size was &ge;15 mm (70 versus 27 percent for &lt;15 mm) and when the vegetation was moderately or severely mobile (62 versus 20 percent for low mobility) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/27\">",
"     27",
"    </a>",
"    ]. Embolic events were particularly frequent when both severely mobile and very large vegetations were present (83 percent).",
"   </p>",
"   <p>",
"    Observational studies suggest that embolic risk generally falls with time after institution of appropriate antibiotic therapy. In one series of 207 patients, the rate of embolization fell from 13 per 1000 patient days during the first week of therapy to less than 1.2 per 1000 patient days after two weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/28\">",
"     28",
"    </a>",
"    ]. A larger series of 1437 patients from the International Collaboration on Endocarditis found that stroke rate decreased from 4.8 to 1.7 per 1000 patient years from the first to the second week of antibiotic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, echocardiographic predictors of emboli still apply after the initiation of antibiotics. In the large study cited above, only 24 percent of observed emboli occurred after the start of antibiotic therapy, but greater vegetation length and mobility were still prognostic factors for these later embolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An initial increase in vegetation size during appropriate antibiotic therapy or large vegetation size also predicted a prolonged healing phase and a higher embolic risk in an earlier report [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a TEE study of 83 IE patients, vegetations that enlarged or remained static rather than regressed during four to eight weeks of therapy were associated with an increased incidence of embolic events (45 versus 17 percent), abscess formation (13 versus 2 percent), valve replacement (45 versus 2 percent), and mortality (10 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of patients with large vegetations but no complications is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When indicated, it is our practice to repeat the TEE after seven days of antibiotic therapy and compare the size of the vegetation(s); dramatic decreases in vegetation size may occur after only one week of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RECOGNITION OF INTRACARDIAC COMPLICATIONS OF ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its role in diagnosing endocarditis, echocardiography is important for recognizing the intracardiac complications associated with endocarditis, including regurgitant valve lesions, valve perforation, and abscess and fistula formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Valvular regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial infiltration and proliferation in valve tissue can destroy the integrity of the leaflet, leading to regurgitation (",
"    <a class=\"graphic graphic_movie graphicRef55154 \" href=\"UTD.htm?21/47/22260\">",
"     movie 3",
"    </a>",
"    ). In general, the etiology of valve deterioration has little impact on the echocardiographic features of severe valvular regurgitation. However, it is sometimes difficult to differentiate a disrupted, prolapsing and flail segment of leaflet from a mobile prolapsing vegetation. Each has the same motion during the cardiac cycle, echocardiographic tissue characteristics are similar, and both may be present in the same location. Measuring a flail leaflet that has been mistaken for a vegetation may lead to miscalculation of risk level or overdiagnosis of endocarditis. Transesophageal echocardiography (TEE) substantially aids distinguishing leaflet from vegetation and this capacity contributes to its advantages as a prognostic and diagnostic tool",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Perivalvular abscess or fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the infectious process spreads beyond the valve leaflets or the cavitary endocardium, it invades the continuous basal myocardium and tissue of the fibrous cardiac skeleton. Early in this process, the organism produces cellulitis, which may be identified as echodense thickening of perivalvular tissue. If tissue necrosis and white cell activity continue, the central portion of this process forms a space-occupying abscess cavity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74507 \" href=\"UTD.htm?4/63/5107\">",
"     image 4C",
"    </a>",
"    ). Abscess formation is most likely with S. aureus infection.",
"   </p>",
"   <p>",
"    Since the myocardial wall is under considerable pressure, the weakened necrotic tissue may become disrupted and the abscess cavity may communicate with either ventricle or a great vessel (",
"    <a class=\"graphic graphic_movie graphicRef65848 \" href=\"UTD.htm?29/38/30306\">",
"     movie 6",
"    </a>",
"    ). In the setting of such a communication, the abscess cavity can also be viewed as a pseudoaneurysm, particularly if it involves the aortic wall directly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/30\">",
"     30",
"    </a>",
"    ]. The distinction between an abscess and pseudoaneurysm can be made with TEE color flow Doppler, which will demonstrate flow into a pseudoaneurysm but not into an abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/31\">",
"     31",
"    </a>",
"    ]. Complete disruption of the wall may lead to a fistulous connection with intracardiac shunting between chambers, most commonly between the aorta and right atrium, left atrium and right ventricle, or left ventricle and right ventricle.",
"   </p>",
"   <p>",
"    The most important feature of myocardial abscess formation is the increased morbidity and mortality (32 to 45 percent in different series) associated with this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/12,32\">",
"     12,32",
"    </a>",
"    ]. Examples of fistulous communications include aorta to left atrium, which is associated with a new continuous murmur, and left ventricle to right atrium. If the abscess extends into the septum, the conduction system may be interrupted or conduction slowed; a right bundle branch block with first degree A-V block may ensue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications and outcome of infective endocarditis\", section on 'Perivalvular abscesses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transesophageal echocardiography has a much greater likelihood of detecting a myocardial abscess than transthoracic echocardiography (TTE) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74507 \" href=\"UTD.htm?4/63/5107\">",
"     image 4C",
"    </a>",
"    ). One study, for example, evaluated 118 patients with endocarditis, 44 (37 percent) of whom had an abscess documented at surgery or autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/12\">",
"     12",
"    </a>",
"    ]. The sensitivity and specificity of TEE were 87 and 95 percent, respectively; the sensitivity of TTE was much lower (28 versus 87 percent with TEE) although the specificity was 99 percent. A similar wide discrepancy in sensitivity (25 versus 100 percent with TEE) was noted in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/34\">",
"     34",
"    </a>",
"    ]. Transthoracic echocardiography is most effective for detecting an anterior abscess at the aortic septal junction because of transducer proximity to this region.",
"   </p>",
"   <p>",
"    While TEE is more sensitive than TTE for detecting an abscess, even TEE may miss a significant number of abscesses in some populations. This was illustrated in a report of 44 patients with surgically identified abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/35\">",
"     35",
"    </a>",
"    ]. Only 21 (48 percent) were detected by TEE. Sixty-one percent of missed abscesses were located at the posterior mitral annulus and the majority of these were associated with a large calcification which may have interfered with abscess detection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications that are best detected with TEE include leaflet perforation (",
"    <a class=\"graphic graphic_movie graphicRef79920 \" href=\"UTD.htm?2/1/2064\">",
"     movie 11",
"    </a>",
"    ), true aneurysm formation, secondary infection of other valves resulting from vegetation contact (for example secondary mitral valve involvement with primary aortic valve endocarditis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/36\">",
"     36",
"    </a>",
"    ], and vegetations on the chamber walls that are struck by the jets of blood passing through the infected valves. As an example, one study that correlated the results of TTE and TEE with anatomic findings at surgery in 88 valves from patients with endocarditis, the sensitivity of TEE for the detection of valve perforation was significantly higher than that of TTE [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/37\">",
"     37",
"    </a>",
"    ]. Transesophageal echocardiography detected perforation in 21 of 22 cases compared to only 10 of 22 by TTE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     RIGHT-SIDED ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vegetations of the tricuspid valve are commonly encountered in populations of intravenous drug users (",
"    <a class=\"graphic graphic_movie graphicRef73652 \" href=\"UTD.htm?22/46/23279\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef70221 \" href=\"UTD.htm?0/29/466\">",
"     movie 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56693 \" href=\"UTD.htm?35/45/36566\">",
"     image 1",
"    </a>",
"    ). Most infections are caused by S. aureus and vegetation size may be a predictor of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/38\">",
"     38",
"    </a>",
"    ]. In one series of 132 cases, there was a marked increase in mortality associated with vegetations greater than 2 cm (33 versus 1.3 percent for smaller vegetations, p&lt;0.001).",
"   </p>",
"   <p>",
"    Infrequently right-sided endocarditis is due to involvement of the pulmonic valve (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65378 \" href=\"UTD.htm?19/34/20015\">",
"     image 4B",
"    </a>",
"    ) or to infection of right ventricular pacemaker or device leads or indwelling catheters (",
"    <a class=\"graphic graphic_movie graphicRef81420 \" href=\"UTD.htm?12/53/13151\">",
"     movie 8",
"    </a>",
"    ). Pulmonic valve endocarditis can often be diagnosed only by transesophageal echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/39\">",
"     39",
"    </a>",
"    ]. Most of the TEE literature on this condition is limited to single-case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most reports of right-sided endocarditis have used TTE. The diagnostic accuracy of TTE and TEE were compared in 48 intravenous drug users suspected of having IE; vegetations were identified in 22 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/41\">",
"     41",
"    </a>",
"    ]. Both techniques were equally sensitive and specific; in no case, did TEE find a vegetation that was overlooked by TTE, although the vegetation was usually better characterized by TEE. It was concluded that TEE was not sufficiently more sensitive to justify its routine use; however, TEE was primarily performed with monoplanar equipment with relatively low carrier frequencies.",
"   </p>",
"   <p>",
"    In our experience, the use of multiplane TEE, higher transducer carrier frequencies (7 mHz), and transgastric views has increased the yield of detecting pulmonic and tricuspid vegetations (",
"    <a class=\"graphic graphic_movie graphicRef81420 \" href=\"UTD.htm?12/53/13151\">",
"     movie 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/39\">",
"     39",
"    </a>",
"    ]. Nevertheless, we current limit the use of TEE to patients with a high index of suspicion for endocarditis in whom the transthoracic echocardiogram is negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PROSTHETIC VALVE ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiographic findings in prosthetic valve endocarditis include vegetations, which may impair leaflet motion, perivalvular abscess and fistula formation, as well as valve rocking indicating valve dehiscence. Paravalvular regurgitation may also indicate prosthetic valve endocarditis but should be compared to any prior paravalvular regurgitation. If prior data are lacking, moderate to severe, but not mild, paravalvular regurgitation should be considered suggestive of endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of echocardiography for detecting prosthetic valve endocarditis is impeded by suboptimal visualization because prosthetic materials are highly reflective and usually block the passage of ultrasound. As a result, prosthetic valves shadow or obscure structures lying behind the valve. As an example, it is usually impossible to image the atrial side of the mitral prosthesis or the arterial side of the aortic prosthesis from an apical transthoracic window.",
"   </p>",
"   <p>",
"    Transesophageal echocardiography solves this problem for mitral prostheses, and improves it for aortic prostheses (",
"    <a class=\"graphic graphic_movie graphicRef58762 \" href=\"UTD.htm?40/16/41230\">",
"     movie 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef74517 \" href=\"UTD.htm?25/30/26082\">",
"     movie 10",
"    </a>",
"    ). However, when both mitral and aortic devices are present, the mitral device tends to obscure the aortic valve. Tricuspid and pulmonic devices pose similar problems.",
"   </p>",
"   <p>",
"    Studies of patients with prosthetic endocarditis who were evaluated with both TEE and transthoracic echocardiography, have found a much higher sensitivity with TEE (82 to 86 versus 36 to 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/34,43-45\">",
"     34,43-45",
"    </a>",
"    ]. As an example, one prospective study compared transthoracic echocardiography and TEE in 114 episodes of endocarditis suspected on clinical grounds [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/45\">",
"     45",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The results of the two tests were concordant in 55 percent of cases; TEE led to a reclassification of the case in 11 percent of patients with native valves and in 34 percent of patients with prosthetic valves.",
"     </li>",
"     <li>",
"      For patients with native valves, transthoracic echocardiography was usually diagnostic in cases where the probability of endocarditis was high on clinical grounds, but TEE substantially aided diagnosis in patients with an intermediate probability of endocarditis.",
"     </li>",
"     <li>",
"      TEE had a positive predictive value of 90 percent for both native and prosthetic valve endocarditis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The negative predictive value of TEE is nearly 100 percent for some populations of patients with native valves. Patients with prosthetic valves are more likely to have a negative TEE in the presence of endocarditis. In patients with prosthetic valves, clinical assessment is especially important.",
"   </p>",
"   <p>",
"    One feature of prosthetic valve endocarditis that should be evaluated by echocardiography but may be missed is prosthetic valve dehiscence. In a study that included 26 patients with prosthetic valve endocarditis, 14 (54 percent) had surgically identified valve dehiscence [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/35\">",
"     35",
"    </a>",
"    ]. Dehiscence was missed on TEE in four cases which all involved an aortic prosthetic valve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiogram is an essential component of the diagnostic evaluation of the patient with suspected endocarditis, and should be performed in all patients with a moderate or high suspicion of this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transthoracic echocardiography and TEE are complementary for comprehensively evaluating hemodynamics and anatomy, but TEE is far superior because of its greater sensitivity in detecting native valve vegetations, prosthetic valve vegetations, perivalvular abscess and other pyogenic complications. A negative TEE makes endocarditis unlikely, and a large vegetation that fails to shrink during therapy connotes a poor prognosis.",
"   </p>",
"   <p>",
"    Based on these considerations and clinical experience, it is recommended that all patients with suspected IE undergo TTE. It is the firm opinion of most experts that they should also have at least one TEE. Regardless of the modality chosen for initial examination, a complete Doppler examination must also be performed.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of valvular heart disease included recommendations on the role of TTE and TEE in IE (",
"    <a class=\"graphic graphic_table graphicRef60777 \" href=\"UTD.htm?32/34/33324\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/2\">",
"     2",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of patients in settings where endocarditis is suspected (such as persistent bacteremia without a known source or high clinical suspicion with negative cultures)",
"     </li>",
"     <li>",
"      Detection and characterization of vegetations on valves and in other sites (as in patients with congenital heart disease)",
"     </li>",
"     <li>",
"      Detection of valvular dysfunction and assessment of hemodynamic severity",
"     </li>",
"     <li>",
"      Detection of associated abnormalities such as shunts or abscesses",
"     </li>",
"     <li>",
"      Re-evaluation of patients in complex settings (such as those with virulent organisms, severe hemodynamic effects, persistent fever or bacteremia, or clinical deterioration)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Surgery in IE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines also made recommendations concerning the timing of surgery in IE [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20617/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several echocardiographic findings were central to these recommendations in patients with native valve IE (",
"    <a class=\"graphic graphic_table graphicRef76266 \" href=\"UTD.htm?37/50/38699\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute aortic regurgitation with tachycardia and early closure of the mitral valve on echocardiography",
"     </li>",
"     <li>",
"      TEE evidence of annular or aortic abscess or a sinus or aortic true or false aneurysm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines concluded that efficacy was less well established for performing surgery for mobile vegetations &gt;10 mm on echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link&amp;anchor=H9#H9\">",
"     \"Surgery for native valve endocarditis\", section on 'Vegetation size'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography is also for helpful in the evaluation of potential candidates for surgery for prosthetic valve IE. TTE and TEE enable identification of valve dysfunction and TEE is particularly valuable for identification of perivalvular extension of infection (",
"    <a class=\"graphic graphic_table graphicRef54251 \" href=\"UTD.htm?28/12/28875\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6438?source=see_link\">",
"     \"Echocardiographic evaluation of prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=see_link\">",
"     \"Surgery for prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/1\">",
"      Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000; 30:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/2\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/3\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/4\">",
"      Hirschfeld DS, Schiller N. Localization of aortic valve vegetations by echocardiography. Circulation 1976; 53:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/5\">",
"      O'Brien JT, Geiser EA. Infective endocarditis and echocardiography. Am Heart J 1984; 108:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/6\">",
"      Gilbert BW, Haney RS, Crawford F, et al. Two-dimensional echocardiographic assessment of vegetative endocarditis. Circulation 1977; 55:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/7\">",
"      Shively BK, Gurule FT, Roldan CA, et al. Diagnostic value of transesophageal compared with transthoracic echocardiography in infective endocarditis. J Am Coll Cardiol 1991; 18:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/8\">",
"      M&uuml;gge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol 1989; 14:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/9\">",
"      Jaffe WM, Morgan DE, Pearlman AS, Otto CM. Infective endocarditis, 1983-1988: echocardiographic findings and factors influencing morbidity and mortality. J Am Coll Cardiol 1990; 15:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/10\">",
"      Burger AJ, Peart B, Jabi H, Touchon RC. The role of two-dimensional echocardiology in the diagnosis of infective endocarditis [corrected]. Angiology 1991; 42:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/11\">",
"      Pedersen WR, Walker M, Olson JD, et al. Value of transesophageal echocardiography as an adjunct to transthoracic echocardiography in evaluation of native and prosthetic valve endocarditis. Chest 1991; 100:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/12\">",
"      Daniel WG, M&uuml;gge A, Martin RP, et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med 1991; 324:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/13\">",
"      Sochowski RA, Chan KL. Implication of negative results on a monoplane transesophageal echocardiographic study in patients with suspected infective endocarditis. J Am Coll Cardiol 1993; 21:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/14\">",
"      Shapiro SM, Young E, De Guzman S, et al. Transesophageal echocardiography in diagnosis of infective endocarditis. Chest 1994; 105:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/15\">",
"      Birmingham GD, Rahko PS, Ballantyne F 3rd. Improved detection of infective endocarditis with transesophageal echocardiography. Am Heart J 1992; 123:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/16\">",
"      Lowry RW, Zoghbi WA, Baker WB, et al. Clinical impact of transesophageal echocardiography in the diagnosis and management of infective endocarditis. Am J Cardiol 1994; 73:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/17\">",
"      Sanfilippo AJ, Picard MH, Newell JB, et al. Echocardiographic assessment of patients with infectious endocarditis: prediction of risk for complications. J Am Coll Cardiol 1991; 18:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/18\">",
"      Sampedro MF, Patel R. Infections associated with long-term prosthetic devices. Infect Dis Clin North Am 2007; 21:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/19\">",
"      Rohmann S, Erbel R, Darius H, et al. Prediction of rapid versus prolonged healing of infective endocarditis by monitoring vegetation size. J Am Soc Echocardiogr 1991; 4:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/20\">",
"      Buda AJ, Macdonald IL, David TE, Kerwin AJ. Rapidly progressive vegetative endocarditis. Acta Cardiol 1982; 37:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/21\">",
"      Kisslo J, Guadalajara JF, Stewart JA, Stack RS. Echocardiography in infective endocarditis. Herz 1983; 8:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/22\">",
"      Tak T, Rahimtoola SH, Kumar A, et al. Value of digital image processing of two-dimensional echocardiograms in differentiating active from chronic vegetations of infective endocarditis. Circulation 1988; 78:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/23\">",
"      M&uuml;gge A. Echocardiographic detection of cardiac valve vegetations and prognostic implications. Infect Dis Clin North Am 1993; 7:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/24\">",
"      Heinle S, Wilderman N, Harrison JK, et al. Value of transthoracic echocardiography in predicting embolic events in active infective endocarditis. Duke Endocarditis Service. Am J Cardiol 1994; 74:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/25\">",
"      De Castro S, Magni G, Beni S, et al. Role of transthoracic and transesophageal echocardiography in predicting embolic events in patients with active infective endocarditis involving native cardiac valves. Am J Cardiol 1997; 80:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/26\">",
"      Vilacosta I, Graupner C, San Rom&aacute;n JA, et al. Risk of embolization after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol 2002; 39:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/27\">",
"      Di Salvo G, Habib G, Pergola V, et al. Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol 2001; 37:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/28\">",
"      Steckelberg JM, Murphy JG, Ballard D, et al. Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med 1991; 114:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/29\">",
"      Dickerman SA, Abrutyn E, Barsic B, et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 2007; 154:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/30\">",
"      Akins EW, Slone RM, Wiechmann BN, et al. Perivalvular pseudoaneurysm complicating bacterial endocarditis: MR detection in five cases. AJR Am J Roentgenol 1991; 156:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/31\">",
"      Tingleff J, Egeblad H, G&oslash;tzsche CO, et al. Perivalvular cavities in endocarditis: abscesses versus pseudoaneurysms? A transesophageal Doppler echocardiographic study in 118 patients with endocarditis. Am Heart J 1995; 130:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/32\">",
"      Leung DY, Cranney GB, Hopkins AP, Walsh WF. Role of transoesophageal echocardiography in the diagnosis and management of aortic root abscess. Br Heart J 1994; 72:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/33\">",
"      Karalis DG, Bansal RC, Hauck AJ, et al. Transesophageal echocardiographic recognition of subaortic complications in aortic valve endocarditis. Clinical and surgical implications. Circulation 1992; 86:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/34\">",
"      Zabalgoitia M, Garcia M. Pitfalls in the echo-Doppler diagnosis of prosthetic valve disorders. Echocardiography 1993; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/35\">",
"      Hill EE, Herijgers P, Claus P, et al. Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome: a 5-year study. Am Heart J 2007; 154:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/36\">",
"      Piper C, Hetzer R, K&ouml;rfer R, et al. The importance of secondary mitral valve involvement in primary aortic valve endocarditis; the mitral kissing vegetation. Eur Heart J 2002; 23:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/37\">",
"      De Castro S, Cartoni D, d'Amati G, et al. Diagnostic accuracy of transthoracic and multiplane transesophageal echocardiography for valvular perforation in acute infective endocarditis: correlation with anatomic findings. Clin Infect Dis 2000; 30:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/38\">",
"      Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. Ann Intern Med 1992; 117:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/39\">",
"      Winslow T, Foster E, Adams JR, Schiller NB. Pulmonary valve endocarditis: improved diagnosis with biplane transesophageal echocardiography. J Am Soc Echocardiogr 1992; 5:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/40\">",
"      Hutchison SJ, Rosin BL, Curry S, Chandraratna PA. Transesophageal Echocardiographic Assessment of Lesions of the Right Ventricular Outflow Tract and Pulmonic Valve. Echocardiography 1996; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/41\">",
"      San Rom&aacute;n JA, Vilacosta I, Zamorano JL, et al. Transesophageal echocardiography in right-sided endocarditis. J Am Coll Cardiol 1993; 21:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/42\">",
"      Ronderos RE, Portis M, Stoermann W, Sarmiento C. Are all echocardiographic findings equally predictive for diagnosis in prosthetic endocarditis? J Am Soc Echocardiogr 2004; 17:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/43\">",
"      Daniel WG, M&uuml;gge A, Grote J, et al. Comparison of transthoracic and transesophageal echocardiography for detection of abnormalities of prosthetic and bioprosthetic valves in the mitral and aortic positions. Am J Cardiol 1993; 71:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/44\">",
"      Alton ME, Pasierski TJ, Orsinelli DA, et al. Comparison of transthoracic and transesophageal echocardiography in evaluation of 47 Starr-Edwards prosthetic valves. J Am Coll Cardiol 1992; 20:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20617/abstract/45\">",
"      Roe MT, Abramson MA, Li J, et al. Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the duke criteria. Am Heart J 2000; 139:945.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5323 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20617=[""].join("\n");
var outline_f20_8_20617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS OF INFECTIVE ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VALVULAR VEGETATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Procedural considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Transducer frequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Commercial instrument and instrument setting variation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Patient physical characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pretest expectations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      M-mode echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Transthoracic echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Transesophageal echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - False positive results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - False negative results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnostic criteria for vegetations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Natural history of vegetations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nonbacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ECHOCARDIOGRAPHIC ESTIMATION OF OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Transthoracic echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Transesophageal echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Vegetation size and embolic risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RECOGNITION OF INTRACARDIAC COMPLICATIONS OF ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Valvular regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Perivalvular abscess or fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      RIGHT-SIDED ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PROSTHETIC VALVE ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Surgery in IE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5323|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/45/36566\" title=\"diagnostic image 1\">",
"      Apical 4 chamber echo endocarditis tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/7/5232\" title=\"diagnostic image 2A\">",
"      Parasternal long axis echo aortic valve vegetations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/0/17411\" title=\"diagnostic image 2B\">",
"      Parasternal echo aortic valve vegetations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/2/25635\" title=\"diagnostic image 3\">",
"      Apical 4 chamber echo vegetations mitral valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/25/3487\" title=\"diagnostic image 4A\">",
"      TEE mitral valve vegetations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/34/20015\" title=\"diagnostic image 4B\">",
"      TEE vegetation pulmonic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/63/5107\" title=\"diagnostic image 4C\">",
"      TTE vs TEE abscess aortic root",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5323|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?22/46/23279\" title=\"movie 1\">",
"      TEE 4 chamber view tricuspid valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?30/9/30867\" title=\"movie 2\">",
"      Parasternal long axis echo aortic valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/47/22260\" title=\"movie 3\">",
"      Aortic valve endocarditis long axis color Doppler echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/28/21954\" title=\"movie 4\">",
"      Parasternal long axis echo close up aortic valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?0/29/466\" title=\"movie 5\">",
"      Apical 4 chamber echo tricuspid valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?29/38/30306\" title=\"movie 6\">",
"      TEE mitral valve aneurysm from endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/39/18035\" title=\"movie 7\">",
"      TEE mitral valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?12/53/13151\" title=\"movie 8\">",
"      TEE bicaval view pacemaker wire vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/16/41230\" title=\"movie 9\">",
"      TEE prosthetic mitral valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?25/30/26082\" title=\"movie 10\">",
"      TEE mechanical mitral valve vegetations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?2/1/2064\" title=\"movie 11\">",
"      TEE mitral valve leaflet perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5323|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/26/9644\" title=\"table 1A\">",
"      Duke criteria for IE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/31/6653\" title=\"table 1B\">",
"      Duke criteria for IE II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/34/33324\" title=\"table 2\">",
"      Guidelines for use of echocardiography in IE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/50/38699\" title=\"table 3\">",
"      Surgery native valve IE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/12/28875\" title=\"table 4\">",
"      Surgery prosthetic valve IE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6438?source=related_link\">",
"      Echocardiographic evaluation of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=related_link\">",
"      Surgery for prosthetic valve endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_8_20618="Differential diagnosis of vulvar lesions";
var content_f20_8_20618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Differential diagnosis of vulvar lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20618/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20618/contributors\">",
"     T Minsue Chen, MD, FAAD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20618/contributors\">",
"     Aileen Langston, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20618/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20618/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/8/20618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/8/20618/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/8/20618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide spectrum of benign, premalignant, and malignant lesions may involve the vulva. The challenge to the clinician is to differentiate between normal variants, benign findings, and potentially serious disease, and this is not always easy.",
"   </p>",
"   <p>",
"    The most useful means of generating a differential diagnosis of vulvar lesions is by morphologic findings (",
"    <a class=\"graphic graphic_table graphicRef82154 \" href=\"UTD.htm?33/29/34267\">",
"     table 1",
"    </a>",
"    ) rather than by symptomatology, which is often nonspecific. Table 2 lists the most common diagnoses of vulvar lesions based on morphology (",
"    <a class=\"graphic graphic_table graphicRef58497 graphicRef74333 \" href=\"UTD.htm?15/10/15534\">",
"     table 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], and Table 3 lists uncommon diagnoses by etiology (",
"    <a class=\"graphic graphic_table graphicRef72003 \" href=\"UTD.htm?39/32/40460\">",
"     table 3",
"    </a>",
"    ). As with any presentation, the possibility of a multifactorial etiology should be considered.",
"   </p>",
"   <p>",
"    An overview of benign vulvar lesions will be provided here. Vulvar intraepithelial neoplasia, vulvar cancer, vulvar dermatitis, and vulvodynia are discussed in detail separately (see individual topic reviews). The general approach to evaluation of vulvar lesions, including the history, physical examination, and diagnostic studies, is also reviewed separately. In all cases, one or more vulvar biopsies should be performed if the lesion is clinically suspicious for malignancy (asymmetry, border irregularity, color variation, rapid change, bleeding, non-healing). If a diagnosis cannot be made confidently by visual inspection and noninvasive methods, or if the lesion does not resolve after standard therapy, then a biopsy should also be strongly considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=see_link\">",
"     \"Diagnostic evaluation of vulvar lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEOPLASIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vulvar intraepithelial neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar intraepithelial neoplasia is a precancerous skin lesion of the vulva that may eventually progress to invasive carcinoma if left untreated. Most vulvar intraepithelial neoplasia lesions are multifocal and located in the nonhair-bearing parts of the vulva. The lesions are often raised",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    verrucous and white (",
"    <a class=\"graphic graphic_picture graphicRef72661 graphicRef78650 \" href=\"UTD.htm?29/56/30600\">",
"     picture 1A-B",
"    </a>",
"    ), but the color may be red (",
"    <a class=\"graphic graphic_picture graphicRef74997 \" href=\"UTD.htm?31/0/31745\">",
"     picture 2",
"    </a>",
"    ), pink, gray, or brown (",
"    <a class=\"graphic graphic_picture graphicRef75216 \" href=\"UTD.htm?20/15/20725\">",
"     picture 3",
"    </a>",
"    ). Macular lesions mostly occur on adjacent mucosal surfaces. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with vulvar cancer present with a unifocal vulvar plaque, ulcer, or mass (fleshy, nodular, or warty) on the labia. Lichen sclerosus and erosive lichen planus may predispose to vulvar cancers (",
"    <a class=\"graphic graphic_picture graphicRef80593 \" href=\"UTD.htm?19/21/19794\">",
"     picture 4",
"    </a>",
"    ). Ulcerations that do not heal, especially in postmenopausal women and women with a history of lichen sclerosis, should be biopsied [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FLESH COLORED PAPULE/NODULE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common flesh colored or non-pigmented papules and nodules are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5433935\">",
"    <span class=\"h2\">",
"     Sebaceous glands and hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sebaceous glands are viewed as normal findings on the vulva. In areas where the epidermis is thin and translucent (ie, inner aspect of labia majora and minora), one can easily identify these variably sized lesions. Stretching the skin can enhance their yellow color and confirm their dermal location (",
"    <a class=\"graphic graphic_picture graphicRef75027 \" href=\"UTD.htm?25/2/25633\">",
"     picture 5",
"    </a>",
"    ). While sebaceous hyperplasia of the face is common and presents as larger yellow papules with a characteristic central dell, sebaceous hyperplasia of the vulva is rare and presents as polypoidal mass covered by normal skin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vestibular papillae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vestibular papillae are discrete, small papules located symmetrically around the edge of and confined to the vestibule; they occur in about 1 percent of women (",
"    <a class=\"graphic graphic_picture graphicRef75027 \" href=\"UTD.htm?25/2/25633\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These lesions are benign and usually asymptomatic, and therefore do not require treatment. They may be confused with condyloma acuminata, except condyloma tend to fuse together and are not confined to the vestibule. Vulvar intraepithelial neoplasia has a more variable appearance, but often presents as a patch. A biopsy can be considered when the diagnosis is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acrochordon (skin tag, fibroepithelial polyp, soft fibroma)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acrochordons (skin tags) are a benign outgrowth of normal skin. They appear as pedunculated lesions on narrow stalks (",
"    <a class=\"graphic graphic_picture graphicRef78524 \" href=\"UTD.htm?11/0/11265\">",
"     picture 6",
"    </a>",
"    ) and tend to be more numerous in patients with diabetes or obesity and in areas of chronic friction. Removal is indicated when the patient is symptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of benign lesions of the skin\", section on 'Acrochordon (skin tag)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bartholin gland (",
"    <a class=\"graphic graphic_picture graphicRef79478 \" href=\"UTD.htm?14/32/14850\">",
"     picture 7",
"    </a>",
"    ), pilonidal, epidermal inclusion and milia (often are referred to erroneously as sebaceous cysts, when in fact there is no sebaceous component), dermoid, Gartner, and mucous cysts are benign lesions, but can be associated with bothersome symptoms; therefore, treatment is often requested by the patient. Epidermoid, dermoid, Gartner, and mucous cysts may also occur in the vagina [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/7\">",
"     7",
"    </a>",
"    ]. Excised tissue should be sent for histologic examination as malignant changes have been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=see_link\">",
"     \"Disorders of Bartholin gland\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4774?source=see_link\">",
"     \"Management of intergluteal pilonidal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H1101420445#H1101420445\">",
"     \"Overview of benign lesions of the skin\", section on 'Epidermoid cyst'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5433960\">",
"    <span class=\"h2\">",
"     Lipomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipomas are benign tumors of fat. These lesions may present as non-pedunculated, subcutaneously located, freely mobile, well-circumscribed mass. Unlike cysts, there is no connection to the overlying epidermis (ie, puncta). They have been reported to occur most commonly on the right anterolateral vulva, mimicking a right inguinal hernia. Imaging studies can confirm the lipomatous characteristics of the tumor. Excision may be indicated if symptomatic (ie, pain), growing, asymmetry,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patient concern to rule out other processes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genital warts (condyloma acuminata)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital warts, caused by human papillomavirus infection, may be of flat, filiform, verrucous, pedunculated, or giant morphology. They may be flesh colored or pigmented (",
"    <a class=\"graphic graphic_picture graphicRef74391 \" href=\"UTD.htm?14/18/14626\">",
"     picture 8",
"    </a>",
"    ). Lesions of secondary syphilis may have a wart-like appearance, but are not true warts (",
"    <a class=\"graphic graphic_picture graphicRef63924 \" href=\"UTD.htm?26/12/26818\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although most genital warts can be diagnosed by visual inspection alone, a biopsy is indicated if there is rapid growth, increased pigmentation, coexisting ulceration, fixation to underlying connective tissue, confluence, or poor response to medical treatment. Treatment may be either destructive (eg, cryotherapy, laser, sharp excision,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30851?source=see_link\">",
"     podophyllum resin",
"    </a>",
"    (podophyllin),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    ) or immunomodulating (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    cream). These modalities are not curative and merely speed clinical resolution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27178?source=see_link\">",
"     \"Treatment of vulvar and vaginal warts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Molluscum contagiosum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molluscum contagiosum are umbilicated (ie, contain a small central pit), translucent or pearly papules due to infection from a member of the poxvirus family (",
"    <a class=\"graphic graphic_picture graphicRef65851 \" href=\"UTD.htm?30/10/30887\">",
"     picture 10",
"    </a>",
"    ). Their presence in an otherwise healthy adult woman may indicate an underlying immunosuppressive disorder. Treatment is similar to that of genital warts: destructive (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"     cantharidin",
"    </a>",
"    , cryotherapy) or immunomodulating (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    cream). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=see_link\">",
"     \"Molluscum contagiosum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Syringoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syringomas are benign neoplasms of the eccrine sweat glands. They commonly involve the lower eyelid and upper malar areas, occurring less frequently in the upper lip, axillae, extremities, buttocks, chest, abdomen, or thigh. Involvement of the vulva is rare (",
"    <a class=\"graphic graphic_picture graphicRef73817 \" href=\"UTD.htm?12/5/12369\">",
"     picture 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Vulvar syringomas typically present as multiple, 1 to 2 mm, flesh-colored to yellow papules arranged symmetrically on the labia majora, but solitary lesions have been reported. Simultaneous involvement of the periorbital skin, cheeks, or neck is common. Most lesions are asymptomatic, but in contrast to lesions elsewhere, heat and sweating, menstruation, or pregnancy may provoke pruritus in vulvar syringomas. Excision or ablation is curative. In some patients, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    or tretinoin has provided symptomatic relief [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5433980\">",
"    <span class=\"h2\">",
"     Lymphedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema may be identified in the vulva and may signify the presence of serious underlying medical conditions resulting in lymphatic dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    damage (ie, congenital lesion, congestive heart failure, obesity, sexually transmitted disease, filariasis, malignancy, contact dermatitis, surgery, portal hypertension). Clinical presentation depends on duration. Acute lymphedema may present as erythema, non-pitting edema, fragile coalescent papules (ie, lymphangiectasia) or larger nodules (ie, lymphangioma). In contrast, chronic lymphedema may present as woody edema, pedunculated polyps and tags, verrucous plaques with loose adherent crust and foul smelling odor (ie, elephantiasis nostra verrucosa). Clinical history and examination of the lower extremity and regional lymph nodes may assist in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/14-21\">",
"     14-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     WHITE PATCH/PLAQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A white patch or plaque may represent post-inflammatory hypopigmentation, which can develop in areas of preexisting inflammation or injury. The intensity and pattern depend upon the underlying process and skin color. Other potential causes of white lesions on the vulva include the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lichen simplex chronicus",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is frequently seen in all types of dermatitis secondary to chronic rubbing or scratching. Clinical features may include raised white or dark colored plaques on the vulva that are commonly associated erosions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excoriations.&nbsp;An increased amount of scale may also be present (",
"    <a class=\"graphic graphic_picture graphicRef68426 graphicRef81018 graphicRef59195 \" href=\"UTD.htm?29/37/30298\">",
"     picture 12A-C",
"    </a>",
"    ). This scale represents hyperkeratosis, thickening of the outermost layer of the skin (stratum corneum).&nbsp;Hyperkeratosis is a histologic finding, not a diagnosis, which may also be present in a variety of other diseases, such as genital warts, vulvar intraepithelial neoplasia, and carcinoma. Biopsy of affected skin may be indicated if the underlying disorder is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=see_link\">",
"     \"Diagnostic evaluation of vulvar lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lichen sclerosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichen sclerosus (kraurosis vulvae) classically presents as well-demarcated white, finely wrinkled, and atrophic patches (",
"    <a class=\"graphic graphic_picture graphicRef78574 \" href=\"UTD.htm?41/38/42597\">",
"     picture 13",
"    </a>",
"    ). Erosions may develop with minor trauma, hemorrhage may be present, and normal genital landmarks may be obliterated with chronic inflammation. Specifically, the labia minora often shrink and adhesions of the labia majora may cover the clitoris. These patients complain of vulvar itching and usually have typical clinical findings that suggest the diagnosis. However, a biopsy may be indicated to exclude malignancy if the lesion is unresponsive to therapy or if lesional skin demonstrates morphologic changes. Patients should be treated medically with a potent topical corticosteroid ointment, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    0.05 percent ointment and followed closely due to their increased risk of malignancy. Non-genital skin lesions may also be present, but do not usually involve the mucous membranes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link\">",
"     \"Vulvar lichen sclerosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vitiligo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitiligo is a depigmenting autoimmune disease characterized by loss of melanocytes, which may be seen on the vulva (",
"    <a class=\"graphic graphic_picture graphicRef80058 \" href=\"UTD.htm?23/35/24127\">",
"     picture 14",
"    </a>",
"    ) as well as on extra-genital skin, particularly periorificial areas and extremities. Depigmented irregular shaped macules and patches may be highlighted with a Wood's light as fluorescent white patches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21193?source=see_link\">",
"     \"Vitiligo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DARK LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormone changes may increase the prominence of hormonally responsive hyperpigmented lesions, such as melanocytic nevi. In addition, post-inflammatory hyperpigmentation may develop in areas of prior skin disease, as discussed above for post-inflammatory hypopigmentation, and may be more evident in patients with darker skin phenotypes. Any lesion clinically suspicious for malignancy (asymmetry, border irregularity, color variation, rapid change, bleeding, non-healing) should be biopsied to exclude premalignant or malignant lesions, such as pigmented vulvar intraepithelial neoplasia, carcinoma, or melanoma. Atypical-appearing pigmented lesions should be excised down to the subcutaneous fat (punch technique or fusiform excision) to ensure complete removal for accurate depth assessment. The shave technique may remove only the most superficial portion of the lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Macule/patch",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Acanthosis nigricans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthosis nigricans typically appears as dark, velvety plaques in axillary and nuchal areas, but may also appear in the groin. Most affected patients are obese. Less commonly, acanthosis nigricans may be a cutaneous manifestation of systemic illness (hyperinsulinemia or malignancy) (",
"    <a class=\"graphic graphic_picture graphicRef53776 \" href=\"UTD.htm?3/7/3198\">",
"     picture 15",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27897?source=see_link\">",
"     \"Acanthosis nigricans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Lentigines and junctional nevi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign genital lentigines and junctional nevi have an identical clinical appearance: well-circumscribed hyperpigmented macules. These can only be differentiated by histology. When extensive, lentigines may be a cutaneous marker for one of several genetic syndromes (eg, Peutz-Jeghers syndrome, LEOPARD syndrome, myxoma syndrome, Laugier-Hunziker syndromes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of benign lesions of the skin\", section on 'Melanocytic nevi'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=see_link&amp;anchor=H2#H2\">",
"     \"Benign pigmented skin lesions other than melanocytic nevi (moles)\", section on 'Lentigo'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Papule/nodule",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Seborrheic keratoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic keratoses are benign epidermal neoplasms that appear as \"stuck-on,\" verrucous papules; pseudo-horn cysts may be appreciated under magnification (",
"    <a class=\"graphic graphic_picture graphicRef54386 graphicRef70317 \" href=\"UTD.htm?1/27/1465\">",
"     picture 16A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H1101421989#H1101421989\">",
"     \"Overview of benign lesions of the skin\", section on 'Seborrheic keratosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dermatofibroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatofibroma usually present as firm, hyperpigmented papules that invaginate (dimple sign) with lateral pressure. It is hypothesized that they arise after trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H1101419831#H1101419831\">",
"     \"Overview of benign lesions of the skin\", section on 'Dermatofibroma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Extramammary (ectopic) breast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extramammary breast tissue may be present as a hyperpigmented nodule on the vulva on the milk line, which extends from the axilla to the groin. Symptoms may develop with pregnancy or menstruation, as ectopic breast tissue is susceptible to hormonal fluctuations. Supernumerary breast tissue may also be associated with renal organ system anomalies, in addition to the same pathology that can affect normally positioned breasts (eg, carcinoma, fibrocystic disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=see_link&amp;anchor=H16#H16\">",
"     \"Breast development and morphology\", section on 'Abnormalities in breast development'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fox-Fordyce disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fox-Fordyce disease is an extremely pruritic, monotonous eruption of minute, dark papules involving apocrine glands (",
"    <a class=\"graphic graphic_picture graphicRef74046 \" href=\"UTD.htm?9/2/9251\">",
"     picture 17",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Kaposi sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar Kaposi sarcoma is rare and consists of dusky erythematous to violaceous papules that may ulcerate and become painful. Extra-genital skin, in particular the oral mucosa, should be examined and human immunodeficiency virus infection should be ruled out. Internal organs (eg, gastrointestinal, pulmonary, and lymphatic systems) can also be affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Compound and intradermal melanocytic nevi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compound melanocytic nevi are usually darker than intradermal nevi; both are often well circumscribed, dark-colored, soft papules. Definitive diagnosis is made with a biopsy and histologic examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of benign lesions of the skin\", section on 'Melanocytic nevi'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Dysplastic nevi and melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysplastic nevi and melanoma are pigmented lesions with irregular borders and variable color: brown, black, pink. Some patients with dysplastic nevi are at increased risk of developing melanoma. Biopsy is indicated when dysplastic nevi or melanoma is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Atypical genital nevi (nevi of special sites)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical genital nevi are a unique subtype of pigmented vulvar lesions that most commonly arise in young women. Although clinically they may be indistinguishable from dysplastic nevi and melanoma, and their histologic features overlap with those of melanoma, atypical genital nevi have a benign clinical course. It is important to be aware of this entity to minimize the risk of over-diagnosis of melanoma and over-treatment. Biopsy, however, may be necessary, especially if changes are noted. The pathology requisition form should clearly indicate the genital location, and an accompanying photograph may also assist the pathologist in rendering a diagnosis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22535182\">",
"    <span class=\"h2\">",
"     Cyclists&rsquo; nodule",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cyclists&rsquo; nodule is a nodule or swelling of vulva in competitive female bicyclists with pathological features showing a mixture of fat, fibroblasts, blood vessels and nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Red macule/patch/plaque",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atopic, irritant contact, and allergic contact dermatitis, and neurodermatitis of the vulva commonly present as erythematous lesions (",
"    <a class=\"graphic graphic_picture graphicRef66955 graphicRef80139 \" href=\"UTD.htm?23/18/23847\">",
"     picture 18A-B",
"    </a>",
"    ). Long-standing dermatitis often manifests with hyperpigmentation and thickening of the skin with accentuation of skin folds (lichenification). Family history of atopy and personal history of asthma and seasonal allergies are commonly associated with atopic dermatitis. Repetitive trauma through excoriation leads to neurodermatitis and hyperkeratosis. Avoidance of offending agents is the mainstay of treatment of contact and allergic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5336?source=see_link\">",
"     \"Dermatitis of the vulva\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Psoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psoriasis involving the groin may be located on the mons, labia majora, inner thighs and buttocks. Psoriasis is characterized by erythematous plaques with thick, silvery, white scale on the scalp, elbow, knees, palms, and soles. The scale has been described as &ldquo;micaceous,&rdquo; resembling the mineral mica with the way the scale reflects light and perfect cleavage plane. The scale may be less evident to nearly absent in intertriginous areas like the vulva. It is often associated with nail changes (",
"    <a class=\"graphic graphic_picture graphicRef56110 \" href=\"UTD.htm?32/48/33540\">",
"     picture 19",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Lichen planus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lichen planus on the vulva is characterized by violaceous, flat-topped papules with lacy, white scales (",
"    <a class=\"graphic graphic_picture graphicRef62561 graphicRef60224 \" href=\"UTD.htm?17/27/17849\">",
"     picture 20A-B",
"    </a>",
"    ). However, friction and maceration may erode these findings, but careful examination of surrounding skin will usually reveal the characteristic lesions. Involved areas of the vestibule or vagina often appear as erythematous erosions and patients may develop shortening and narrowing of the vagina. Oral lesions are also common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=see_link\">",
"     \"Vulvar lichen planus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Plasma cell vulvitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma cell vulvitis (Zoon's) appears as a tender, moist, demarcated erythematous plaque of the vestibule and, rarely, the clitoris (",
"    <a class=\"graphic graphic_picture graphicRef75171 graphicRef51099 \" href=\"UTD.htm?37/58/38825\">",
"     picture 21A-B",
"    </a>",
"    ). Oral and vaginal involvement are not usually seen. On histological examination, plasma cells contribute to one-half of the dermal infiltrate. Plasma cell vulvitis is a diagnosis of exclusion after more common conditions (eg, infection, contact dermatitis psoriasis, lichen planus, vulvar intraepithelial neoplasia) have been ruled out. A topical corticosteroid may be useful in some cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Atrophic vulvitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophic vulvitis is a manifestation of hypoestrogenism; although the vagina is much more sensitive to estrogen deprivation than the vulva. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"    </a>",
"    .) Atrophy of the vestibule and vulva usually appears erythematous and erosions may be seen with long-standing decreased estrogen levels (",
"    <a class=\"graphic graphic_picture graphicRef61735 \" href=\"UTD.htm?12/45/13023\">",
"     picture 22",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Hailey-Hailey",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hailey-Hailey disease (benign familial pemphigus) is a rare skin disorder that typically affects the intertriginous areas. It is characterized by vesicles and erythematous papules with a peripheral scaling border on flexural surfaces and acantholysis on histologic examination (",
"    <a class=\"graphic graphic_picture graphicRef80862 \" href=\"UTD.htm?34/63/35828\">",
"     picture 23",
"    </a>",
"    ). Burning and itching accompany the eruption. About three quarters of patients have asymptomatic longitudinal white bands on their nails. The disorder is inherited in autosomal dominant fashion, caused by a defect in the gene ATP2C1 that codes for a calcium and manganese transport ATPase of the Golgi apparatus. The diagnosis is established through histologic demonstration of epidermal acantholysis.",
"   </p>",
"   <p>",
"    Most patients achieve satisfactory therapeutic results with topical corticosteroids and avoidance of trauma to the affected area(s). Ablative, surgical modalities may be necessary in more extensive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic lesions. Botulinum toxin type A injection has been used as an adjunct to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of erythematous vulvar lesions should also include infections. Candida infection presents as moist erythema with satellite lesions and occasionally pustules (",
"    <a class=\"graphic graphic_picture graphicRef70637 graphicRef51710 \" href=\"UTD.htm?11/26/11689\">",
"     picture 24A-B",
"    </a>",
"    ). Excessive vaginal discharge from bacterial vaginosis or trichomoniasis may contribute to erythema and maceration of vulvar skin.",
"   </p>",
"   <p>",
"    Saline and potassium hydroxide wet preparation, amine odor test, and pH determination can be performed to confirm the diagnosis. A yeast culture on Sabouraud's medium is indicated if the wet prep is negative, but clinical suspicion remains high and patient has recurrence despite treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5434289\">",
"    <span class=\"h2\">",
"     Erythrasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythrasma is a desquamative condition caused by Corynebacterium minutissimum. It is an uncommon vulvar infection appearing as a hyperpigmented and erythematous patch, similar to Candida infection. Diagnosis may be confirmed by its characteristic coral-red fluorescence under the Wood's lamp or with a biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Extramammary Paget disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extramammary Paget disease, an intraepithelial adenocarcinoma, accounts for less than 1 percent of all vulvar malignancies. Most patients are 60 to 80 years old and Caucasian. Pruritus is the most common symptom. The lesion has an eczematoid appearance; it is well-demarcated and has slightly raised edges and a red background, often dotted with small, pale islands and a moist appearance (",
"    <a class=\"graphic graphic_picture graphicRef61775 \" href=\"UTD.htm?19/58/20391\">",
"     picture 25",
"    </a>",
"    ). It is usually multifocal and may occur anywhere on the vulva, mons,",
"    <span class=\"nowrap\">",
"     perineum/perianal",
"    </span>",
"    area, or inner thigh. Diagnosis is often delayed. Biopsy should be performed if dermatitis does not respond to treatment recommendations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link&amp;anchor=H12#H12\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\", section on 'Extramammary Paget disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Red papule/nodule",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Urticaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria manifests as an intensely pruritic, circumscribed, raised, and erythematous wheal with central pallor. It may be associated with various triggers (eg, medication, food, insect bite, topical products, stress). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Cherry angioma (Campbell de Morgan lesion)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cherry angiomas are discrete benign red papules; they are often present on the trunk and rarely occur on the vulva (",
"    <a class=\"graphic graphic_picture graphicRef63468 \" href=\"UTD.htm?40/55/41841\">",
"     picture 26",
"    </a>",
"    ). Treatment by destructive modalities (eg surgery, cautery) is often requested on lesions located in areas of persistent trauma by clothing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of benign lesions of the skin\", section on 'Cherry angioma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Angiokeratoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiokeratomas are uncommon, benign, violaceous papules with overlying scale (",
"    <a class=\"graphic graphic_picture graphicRef64428 \" href=\"UTD.htm?9/11/9399\">",
"     picture 27",
"    </a>",
"    ). They are usually unilateral, multiple in number, and measure less than 1 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/23\">",
"     23",
"    </a>",
"    ]. In most patients, the lesions are asymptomatic and do not require treatment; however, intermittent bleeding, pruritus, and pain can occur. If lesions are widespread on the trunk, Fabry syndrome should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Urethral lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A midline polypoid lesion may be a urethral caruncle or urethral prolapse. These entities are associated with hypoestrogenism; a urethral origin distinguishes them from true vulvar lesions. Associated symptoms include bleeding and urinary tract symptomatology. In general, biopsy of lesions suspicious for malignancy must be performed carefully due to the potential for urethral injury. Satisfactory treatment may be achieved with topical estrogen cream alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Endometriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriosis most often develops after vulvar implantation of endometrial tissue following a surgical procedure. These violaceous papules may become symptomatic with hormone fluctuations, especially during menses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link\">",
"     \"Overview of the treatment of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5434296\">",
"    <span class=\"h3\">",
"     Varicosities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vulvar varicosities can be seen in the setting of venous dysfunction and pathology (ie, portal hypertension, pregnancy). Clinically, these lesions appear as tubular or grape-like structures that may protrude from the skin and enlarge with increased abdominal pressure (ie, valsalva, position, coughing). Examination of the lower extremities may also demonstrate venous changes of the skin (ie, spider veins, varicose veins, ulceration, venous stasis, phlebitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     PUSTULES, VESICLES, AND EROSIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Folliculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folliculitis may develop in any hair-bearing surface, and therefore may be seen on the mons or labia majora. The pustules are folliculocentric and may have a hair at the center of each lesion (",
"    <a class=\"graphic graphic_picture graphicRef68351 \" href=\"UTD.htm?18/37/19024\">",
"     picture 28",
"    </a>",
"    ); Staphylococcus aureus can be cultured from the skin lesions. Keratosis pilaris may be confused with folliculitis; in contrast, keratosis pilaris lesions have a keratin plug at each follicular ostia and are typically found on the lateral arms, anterior thighs, buttock, and less commonly, the trunk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=see_link\">",
"     \"Folliculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=see_link\">",
"     \"Approach to the patient with pustular skin lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Furunculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Furunculosis and carbuncles may develop with long-standing, severe folliculitis. Inflamed cysts are erythematous, tender nodules that develop as a result of rupture of contents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection. Pain, warmth, fluctuance, and puncta may be evident. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=see_link\">",
"     \"Skin abscesses, furuncles, and carbuncles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Hidradenitis suppurativa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with hidradenitis suppurativa commonly have groin disease, as well as axillary lesions. Hidradenitis suppurativa initially manifests with pruritus, erythema, and local hyperhidrosis. Occlusion of a hair follicle results in a firm, pea-sized nodule or cyst, similar to the comedones of acne that can rupture spontaneously and discharge purulent material (",
"    <a class=\"graphic graphic_picture graphicRef77990 \" href=\"UTD.htm?37/25/38289\">",
"     picture 29",
"    </a>",
"    ). As the area heals, it becomes fibrotic and new nodules develop adjacent to the original lesions. Some lesions rupture spontaneously, leading to sinus tract formation deep within the cutaneous tissue; others remain as indurated inflammatory masses. Hyperpigmentation, scars, and pitting are seen on the skin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Candida",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida infection of the skin can be associated with pustules, as well as moist erythema and satellite lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus (HSV), when occurring as a primary infection, usually exhibits multiple, painful vesicles or ulcerating lesions (",
"    <a class=\"graphic graphic_picture graphicRef61107 graphicRef76083 graphicRef80959 \" href=\"UTD.htm?37/51/38714\">",
"     picture 30A-C",
"    </a>",
"    ). It also often appears as grouped (herpetiform distribution) vesicles on an erythematous base, whereas vesicles arranged in a dermatomal (zosteriform) distribution are most likely herpes zoster. Vesicles, however, may not always be evident due to the moisture and friction in this area. Both may present with a prodrome of fever, malaise, and lymphadenopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Scabies and insect bites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both scabies and insect bites should also be considered in the differential for pustular lesions on the vulva (",
"    <a class=\"graphic graphic_picture graphicRef63563 \" href=\"UTD.htm?6/10/6305\">",
"     picture 31",
"    </a>",
"    ) if household contacts are also symptomatic. Burrows may be evident on wrists, hands and web spaces. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link\">",
"     \"Scabies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=see_link\">",
"     \"Insect bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Bullous impetigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous impetigo is due to Staphylococcus infection and presents with flaccid vesicles and honey colored crust surrounded by a collar of scale. Lesions are commonly found on the face and intertriginous areas (skin folds). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=see_link\">",
"     \"Impetigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Fixed drug reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed drug reactions usually demonstrate discrete, hyperpigmented bullae or erosions that recur in the exact same location with repeat medication administration (",
"    <a class=\"graphic graphic_picture graphicRef51381 \" href=\"UTD.htm?41/39/42612\">",
"     picture 32",
"    </a>",
"    ). Obtaining a drug history, including herbal supplements, is essential for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/26\">",
"     26",
"    </a>",
"    ]. The most common drugs associated with these reactions are phenolphthalein,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , NSAIDS, and sulfonamides. Fixed drug eruption of the vulva is uncommon, but should be considered in women with acute or recurrent vulvitis, particularly in the setting of nonspecific histopathology, negative bacteriology, and resistance to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/27\">",
"     27",
"    </a>",
"    ]. Improvement should occur within two weeks of stopping the causative drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link&amp;anchor=H11#H11\">",
"     \"Drug eruptions\", section on 'Fixed drug eruption'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Erythema multiforme",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema multiforme presents as an acute eruption characterized by distinctive, fixed, target lesions with dusky, violaceous centers and bullae. It has no prodrome and a typically benign clinical course. Unlike a fixed drug reaction, lesions are smaller and more numerous. Palms, soles, and other mucous membranes are also commonly affected. A history of preceding herpes simplex virus infection, upper respiratory infection, or the recent administration of a new medication (eg, NSAIDs, sulfonamides, anti-convulsants, antibiotics) may be elicited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Blistering diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous pemphigoid (",
"    <a class=\"graphic graphic_picture graphicRef78207 graphicRef57255 \" href=\"UTD.htm?42/10/43176\">",
"     picture 33A-B",
"    </a>",
"    ), cicatricial pemphigoid, epidermolysis bullosa acquisita, pemphigus vulgaris, and pemphigus vegetans are autoimmune blistering disorders that can develop on the vulva. Vesicles and bullae are rarely intact. Erosions are usually seen due to the fragile nature of lesions and frictional trauma. Older lesions may be cloudy or hemorrhagic. Although usually regarded at non-scarring processes, labial adhesions, narrowing of the introitus, obliteration of vaginal space, urethral meatal stenosis, and loss of genital landmarks may develop with chronic, uncontrolled disease (",
"    <a class=\"graphic graphic_picture graphicRef54032 \" href=\"UTD.htm?11/30/11746\">",
"     picture 34",
"    </a>",
"    ). Nasal, ocular, pharyngeal, esophageal, and upper airway mucosa may be similarly affected.",
"   </p>",
"   <p>",
"    These lesions are often clinically indistinguishable in the absence of histopathology with immunofluorescence studies. Like other autoimmune diseases, diagnosis of any of these blistering disorders may confer an increased risk of concurrent autoimmune diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pemphigus vulgaris rarely involves the female genital tract [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/28\">",
"     28",
"    </a>",
"    ]. When vulvar disease occurs, extensive disease at other sites is invariably present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h1\">",
"     ULCER/FISSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcers and fissures can be caused by infection, malignancy or systemic disease with vulvar involvement. Chronic excoriation and trauma may also result in angulated, irregular, linear erosions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ulcers. Ulcerative lesions should be biopsied if malignancy cannot be excluded clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is the most common cause of nonhealing, crusted, and ulcerated lesions. Serologic studies and culture will help in diagnosis of infectious etiologies. In patients who have traveled to tropical areas, vulvar manifestations of a tropical disease should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Such infections may or may not be transmitted sexually. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The syphilitic chancre is characteristically singular, nontender with a clean, firm base, developing several weeks after exposure (",
"      <a class=\"graphic graphic_picture graphicRef73119 \" href=\"UTD.htm?8/57/9105\">",
"       picture 35",
"      </a>",
"      ); lymphadenopathy may be present. Large, raised, gray to white lesions, involving warm, moist areas such as mucous membranes in the mouth and perineum, may develop in some patients during secondary syphilis. These are referred to as condylomata lata (",
"      <a class=\"graphic graphic_picture graphicRef79092 \" href=\"UTD.htm?30/28/31169\">",
"       picture 36",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Herpes simplex virus infection may present with multiple painful, grouped, and discrete ulcers (",
"      <a class=\"graphic graphic_picture graphicRef61107 \" href=\"UTD.htm?6/24/6531\">",
"       picture 30A",
"      </a>",
"      ); lymphadenopathy may also be present. Lesions associated with recurrent herpes outbreaks may appear as vesicles, erosions, ulcers or fissures. (See",
"      <a class=\"local\" href=\"#H49\">",
"       'Herpes simplex virus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chancroid ulcer has a gray or purulent base; lymphadenopathy is characteristically fluctuant (ie, buboes) and may break down at a single site with purulent drainage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=see_link\">",
"       \"Chancroid\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphogranuloma venereum is a genital ulcer disease caused by Chlamydia trachomatis. The initial lesion consists of painless, shallow ulcers; fluctuant lymph nodes may develop both above and below the inguinal ligament (groove sign) with multiple fistulae. This infection is found most frequently in tropical and subtropical areas of the world. The diagnosis is difficult to establish on clinical grounds alone and frequently relies upon serologic testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=see_link\">",
"       \"Lymphogranuloma venereum\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Granuloma inguinale (Klebsiella granulomatis, formerly called Calymmatobacterium granulomatis) is another cause of genital ulcers. Diagnosis is by histopathology, as the organism cannot be cultured. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"       \"Approach to the patient with genital ulcers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition, the antiviral medicine",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      , used to treat herpetic infections, can cause painful vulvar and oral ulcerations or bullae [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link&amp;anchor=H10#H10\">",
"       \"Foscarnet: An overview\", section on 'Genital ulcerations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lipsch&uuml;tz vulvar ulceration is a diagnosis of exclusion. It should be considered when infectious and non-infectious causes of ulceration have been excluded and there is no history of sexual contact. Lymphadenopathy may be present, as well as an acute onset of malaise, fever, and painful vulvar ulcers that heal spontaneously [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancy should also be considered in the differential diagnosis of vulvar ulceration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Systemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying systemic diseases may present with ulceration of the vulva.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hidradenitis suppurativa commonly occurs in the genital and perianal regions with skin ulceration, as well as comedones, fistula, cysts, and nodules (see",
"      <a class=\"local\" href=\"#H47\">",
"       'Hidradenitis suppurativa'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Behcet's disease requires the presence of recurrent oral ulceration, in the absence of other clinical explanations, and two of the following: recurrent genital ulceration (",
"      <a class=\"graphic graphic_picture graphicRef74586 \" href=\"UTD.htm?43/21/44372\">",
"       picture 37",
"      </a>",
"      ), eye lesions, skin lesions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a pathergy test. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Crohn's disease is an inflammatory bowel disease with a tendency for linear fissures in the genital folds (knife cut sign). Lesions may be contiguous with the rectum or metastatic from the involved bowel. Several examples of Crohn&rsquo;s disease of the vulva are shown in the pictures (",
"      <a class=\"graphic graphic_picture graphicRef61865 graphicRef69563 \" href=\"UTD.htm?38/62/39912\">",
"       picture 38A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef73032 \" href=\"UTD.htm?29/32/30212\">",
"       picture 39",
"      </a>",
"      ). Abdominal pain and bloody diarrhea are usually associated [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"       \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epstein Barr virus can affect virtually any organ system and has been associated with such diverse disease manifestations as pneumonia, myocarditis, pancreatitis, mesenteric adenitis, myositis, glomerulonephritis, and genital ulceration [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. There have been case reports of painful genital ulcers developing during an episode of serologically-confirmed primary Epstein-Barr virus infection with no other documented etiology (",
"      <a class=\"graphic graphic_picture graphicRef58748 \" href=\"UTD.htm?28/49/29457\">",
"       picture 40",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link\">",
"       \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Langerhans cell histiocytosis may involve one or more body systems (ie, skin, bone, liver, hypothalamus). Isolated vulvar lesions have been reported, most commonly as ulcerations. Vulvar induration and papules have also been reported. Nongenital skin should be examined for seborrheic dermatitis-like rash in intertriginous locations and petechial lesions. Prognosis is dependent on degree of organ involvement. Biopsy of lesional skin, laboratory and imaging studies, as well as a thorough history and physical examination, will aid in diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, drug ingestion (eg, nicorandil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    ) has been associated with vulval ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Topical formulations have also been reported to cause erosions and ulceration when applied to the vulva (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of vulvar disorders may be challenging, as few randomized trials have been performed. Referral to a specialist (gynecologist, dermatologist) or vulvar clinic is indicated if initial management fails. Patients should also be informed of available written and on-line educational resources and support groups for women with vulvar disorders.",
"   </p>",
"   <p>",
"    General principles in the treatment of vulvar disease are reviewed below [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/2,43,44\">",
"     2,43,44",
"    </a>",
"    ]. The treatments of specific vulvar disorders are discussed in separate topic reviews on each subject.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h2\">",
"     Vulvar skin care",
"    </span>",
"    &nbsp;&mdash;&nbsp;General principles of good vulvar hygiene are described in the table (",
"    <a class=\"graphic graphic_table graphicRef64538 \" href=\"UTD.htm?35/49/36635\">",
"     table 4",
"    </a>",
"    ). Patients should be counseled on the importance of avoiding potential irritants to the vulva.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h2\">",
"     Soaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic relief of pruritus, burning,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stinging may be achieved with lukewarm soaks lasting 10 to 20 minutes each two to three times per day. Solutions used include baking soda and tap water, plain tap water, Burrow's solution, and colloidal oatmeal mixtures. Soaks debride crust and restore the physiologic environment; however, care should be taken to avoid over-drying or macerating the skin. Vulvar skin should be gently patted dry after each soak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h2\">",
"     Lubricants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lubricants create a moisture barrier. They should be applied immediately after soaking to retard evaporation and prolong the soothing effect. We suggest use of simple products with minimal ingredients to reduce the risk of irritant or contact dermatitis. Options include petrolatum, olive oil, hydrogenated vegetable oil, and A &amp; D ointment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h2\">",
"     Topical analgesics and oral antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/5/17491?source=see_link\">",
"     pramoxine",
"    </a>",
"    ) and oral antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"     fexofenadine",
"    </a>",
"    ) may provide additional relief from pain and pruritus. Topical antihistamines may cause allergic contact dermatitis and subsequent oral ingestion of a related drug could lead to anaphylaxis. Therefore, their use as a topical agent is not advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h2\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical estrogen medicaments may be applied to the vulva as needed for immediate relief of symptomatic atrophy of the vulva. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66\">",
"    <span class=\"h2\">",
"     Antimicrobial drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmed infections are treated with the appropriate antimicrobial agent (see individual topic reviews). Follow-up visits are recommended to ensure resolution, adjust therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67\">",
"    <span class=\"h2\">",
"     Antiinflammatory agents (oral or topical)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory processes may be treated with immunomodulating medications, such as glucocorticoids,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"      tacrolimus",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"      pimecrolimus",
"     </a>",
"     ,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Disorders that may benefit from this pharmacologic class include lichen sclerosis, dermatitis, psoriasis, lichen planus, pemphigus, Behcet's disease, and Crohn's disease. The specific treatment depends upon the diagnosis, percent of body surface area involved, and impact on quality of life. If the clinician is not experienced in use of these medications, coordinating care with a vulvar or dermatology specialist is helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68\">",
"    <span class=\"h2\">",
"     Combination topical antimicrobial and anti-inflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Usefulness of these drugs is controversial and remains to be demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery or other destructive methods (eg, laser) may be indicated to remove symptomatic lesions, dysplasia, and neoplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geriatric, immunocompromised, and pediatric patient populations require special considerations in the evaluation and treatment of vulvar lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71\">",
"    <span class=\"h2\">",
"     Geriatric",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two primary age-related etiologies of vulvar lesions in postmenopausal women are atrophy due to hypoestrogenemia and cancer. Vulvar cancers and precancerous lesions (vulvar intraepithelial neoplasia) must be considered in postmenopausal women with vulvovaginal complaints or lesions. These lesions can be asymptomatic or have nonspecific symptoms such as itching. There is no typical appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/8/20618/abstract/45\">",
"     45",
"    </a>",
"    ]; thus, any lesion or symptom without a clear diagnosis should be biopsied and the vulva examined with a colposcope. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=see_link\">",
"     \"Vulvar intraepithelial neoplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=see_link\">",
"     \"Vulvar cancer: Clinical manifestations, diagnosis, and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72\">",
"    <span class=\"h2\">",
"     Immunocompromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised patients are at risk for severe manifestations of common infections, as well as atypical infections (",
"    <a class=\"graphic graphic_table graphicRef57626 \" href=\"UTD.htm?8/60/9164\">",
"     table 5",
"    </a>",
"    ). In addition, immunocompromised women are prone to development of certain types of premalignant and malignant disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link\">",
"     \"HIV infection and malignancy: Management considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73\">",
"    <span class=\"h2\">",
"     Pediatric",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and management of vulvovaginal complaints in girls are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link\">",
"     \"Vulvovaginal complaints in the prepubertal child\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most useful means of generating a differential diagnosis of vulvar lesions is by morphologic findings rather than by symptomatology, which is often nonspecific. In all patients, one or more vulvar biopsies should be performed if the lesion is clinically suspicious for malignancy (asymmetry, border irregularity, color variation, rapid change, bleeding, non-healing). Additional indications for biopsy are if a diagnosis cannot be made confidently by visual inspection and noninvasive methods, if the lesion does not resolve after standard therapy, or to address patient concern. Any lesion on the vulva that is not known to be benign warrants biopsy. An ulcerative lesion that does not heal may need additional and more extensive biopsy despite an initial negative office biopsy result. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common flesh colored lesions are sebaceous glands, vestibular papillae, skin tags, cysts, and infections (warts, molluscum contagiosum). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Flesh colored papule/nodule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common white lesions are lichen sclerosus, lichen simplex chronicus, and vitiligo. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'White patch/plaque'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brown, black, or red vulvar lesions can be due to a wide variety of benign, infectious, inflammatory, and malignant conditions. We recommend that any atypical-appearing dark lesion be biopsied to exclude premalignant or malignant lesions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Dark lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pustules, vesicles, and erosions are usually related to infection or inflammation. (See",
"      <a class=\"local\" href=\"#H44\">",
"       'Pustules, vesicles, and erosions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ulcers and fissures can be caused by infection, malignancy or systemic disease with vulvar involvement. (See",
"      <a class=\"local\" href=\"#H55\">",
"       'Ulcer/fissure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General principles of treatment of vulvar disorders include good hygiene and soaks for symptomatic relief. Specific hormonal, antimicrobial, immunomodulating, antiinflammatory, or surgical therapies depend on the specific diagnosis. (See",
"      <a class=\"local\" href=\"#H60\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/1\">",
"      Fischer GO. The commonest causes of symptomatic vulvar disease: a dermatologist's perspective. Australas J Dermatol 1996; 37:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/2\">",
"      Foster DC. Vulvar disease. Obstet Gynecol 2002; 100:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/3\">",
"      Spencer RJ, Young RH, Goodman A. The risk of squamous cell carcinoma in persistent vulvar ulcers. Menopause 2011; 18:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/4\">",
"      Al-Daraji WI, Wagner B, Ali RB, McDonagh AJ. Sebaceous hyperplasia of the vulva: a clinicopathological case report with a review of the literature. J Clin Pathol 2007; 60:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/5\">",
"      Welch JM, Nayagam M, Parry G, et al. What is vestibular papillomatosis? A study of its prevalence, aetiology and natural history. Br J Obstet Gynaecol 1993; 100:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/6\">",
"      Salvini C, De Magnis A. Multiple papillae on labia minora. CMAJ 2008; 179:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/7\">",
"      Eilber KS, Raz S. Benign cystic lesions of the vagina: a literature review. J Urol 2003; 170:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/8\">",
"      Oh JT, Choi SH, Ahn SG, et al. Vulvar lipomas in children: an analysis of 7 cases. J Pediatr Surg 2009; 44:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/9\">",
"      Garman M, Metry D. Vulvar syringomas in a 9-year-old child with review of the literature. Pediatr Dermatol 2006; 23:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/10\">",
"      Huang YH, Chuang YH, Kuo TT, et al. Vulvar syringoma: a clinicopathologic and immunohistologic study of 18 patients and results of treatment. J Am Acad Dermatol 2003; 48:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/11\">",
"      Miranda JJ, Shahabi S, Salih S, Bahtiyar OM. Vulvar syringoma, report of a case and review of the literature. Yale J Biol Med 2002; 75:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/12\">",
"      S&aacute;nchez TS, Daud&eacute;n E, Casas AP, Garc&iacute;a-D&iacute;ez A. Eruptive pruritic syringomas: treatment with topical atropine. J Am Acad Dermatol 2001; 44:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/13\">",
"      G&oacute;mez MI, P&eacute;rez B, Aza&ntilde;a JM, et al. Eruptive syringoma: treatment with topical tretinoin. Dermatology 1994; 189:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/14\">",
"      McDougal WS. Lymphedema of the external genitalia. J Urol 2003; 170:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/15\">",
"      D'Antonio A, Caleo A, Boscaino A, et al. Vulvar lymphoedematous pseudotumours mistaken for aggressive angiomyxoma: report of two cases. Gynecol Obstet Invest 2010; 69:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/16\">",
"      Talwar A, Puri N, Sandhu HP. Vulval lymphoedema following pulmonary tuberculosis. Int J STD AIDS 2009; 20:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/17\">",
"      Okur MI, K&ouml;se R, Yildirim AM, Cobanolu B. Lymphangiectasia of the vulva accompanying congenital lymphedema. Dermatol Online J 2009; 15:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/18\">",
"      Adesiyun AG, Samaila MO. Huge filarial elephantiasis vulvae in a Nigerian woman with subfertility. Arch Gynecol Obstet 2008; 278:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/19\">",
"      Lockwood-Rayermann S. Lymphedema in gynecologic cancer survivors: an area for exploration? Cancer Nurs 2007; 30:E11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/20\">",
"      Mu XC, Tran TA, Dupree M, Carlson JA. Acquired vulvar lymphangioma mimicking genital warts. A case report and review of the literature. J Cutan Pathol 1999; 26:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/21\">",
"      Gupta SC, Misra V, Gupta AK. Cavernous lymphangioma in the vulva. Trop Doct 1998; 28:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/22\">",
"      McCluggage WG, Smith JH. Reactive fibroblastic and myofibroblastic proliferation of the vulva (Cyclist's Nodule): A hitherto poorly described vulval lesion occurring in cyclists. Am J Surg Pathol 2011; 35:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/23\">",
"      Cohen PR, Young AW Jr, Tovell HM. Angiokeratoma of the vulva: diagnosis and review of the literature. Obstet Gynecol Surv 1989; 44:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/24\">",
"      Bell D, Kane PB, Liang S, et al. Vulvar varices: an uncommon entity in surgical pathology. Int J Gynecol Pathol 2007; 26:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/25\">",
"      Gearhart PA, Levin PJ, Schimpf MO. Expanding on earlier findings A vulvar varicosity grew larger with each pregnancy. Am J Obstet Gynecol 2011; 204:89.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/26\">",
"      Sehgal VH, Gangwani OP. Genital fixed drug eruptions. Genitourin Med 1986; 62:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/27\">",
"      Fischer G. Vulvar fixed drug eruption. A report of 13 cases. J Reprod Med 2007; 52:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/28\">",
"      Malik M, Ahmed AR. Involvement of the female genital tract in pemphigus vulgaris. Obstet Gynecol 2005; 106:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/29\">",
"      Okoduwa C, Heller DS. Vulvar diseases of the tropics: a review. J Reprod Med 2009; 54:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/30\">",
"      Richens J. Genital manifestations of tropical diseases. Sex Transm Infect 2004; 80:12.",
"     </a>",
"    </li>",
"    <li>",
"     Edwards, L. Genital dermatology atlas. Lippincott, Williams and Wilkins 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/32\">",
"      Al&eacute;s-Fern&aacute;ndez M, Rodr&iacute;guez-Pichardo A, Garc&iacute;a-Bravo B, et al. Three cases of Lipschutz vulval ulceration. Int J STD AIDS 2010; 21:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/33\">",
"      Hern&aacute;ndez-N&uacute;&ntilde;ez A, C&oacute;rdoba S, Romero-Mat&eacute; A, et al. Lipsch&uuml;tz [corrected] ulcers--four cases. Pediatr Dermatol 2008; 25:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/34\">",
"      Barnes CJ, Ali&oacute; AB, Cunningham BB, Friedlander SF. Epstein-Barr virus-associated genital ulcers: an under-recognized disorder. Pediatr Dermatol 2007; 24:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/35\">",
"      Hudson LB, Perlman SE. Necrotizing genital ulcerations in a premenarcheal female with mononucleosis. Obstet Gynecol 1998; 92:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/36\">",
"      Ishigaki H, Hatta N, Yamada M, et al. Localised vulva Langerhans cell histiocytosis. Eur J Dermatol 2004; 14:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/37\">",
"      Triantafyllidou O, Giannakopoulos K, Pergialiotis V, et al. Pure vulvar Langerhans cell histiocytosis: a case report and literature review. Eur J Gynaecol Oncol 2009; 30:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/38\">",
"      Fraser SJ, Pinion SB, Adamson B, Allan SJ. Vulval ulceration induced by the potassium-channel activator Nicorandil: a case series of five patients. BJOG 2009; 116:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/39\">",
"      Chan SK, Harris MD, Baldwin PJ, Sterling JC. Vulvovaginal ulceration during prolonged treatment with nicorandil. BJOG 2009; 116:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/40\">",
"      Caumes E, Gatineau M, Bricaire F, et al. Foscarnet-induced vulvar erosion. J Am Acad Dermatol 1993; 28:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/41\">",
"      Aguirrebengoa K, Gonz&aacute;lez R, O&ntilde;ate J, et al. [Foscarnet related vulvar ulcers. Description of 2 AIDS patients]. Enferm Infecc Microbiol Clin 1995; 13:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/42\">",
"      Kaya TI, Tursen U, Ikizoglu G. Large genital ulcers in a patient with Beh&ccedil;et's disease associated with imiquimod cream treatment for external genital warts. Clin Exp Dermatol 2008; 33:783.",
"     </a>",
"    </li>",
"    <li>",
"     Lynch, P, Edwards, L. Genital dermatology. Churchill Livingstone, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/8/20618/abstract/44\">",
"      Turner ML, Marinoff SC. General principles in the diagnosis and treatment of vulvar diseases. Dermatol Clin 1992; 10:275.",
"     </a>",
"    </li>",
"    <li>",
"     Curtis, MG, Hopkins, MP. Glass's Office Gynecology, fifth edition. Lippincott, Williams and Wilkins 1999.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5412 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20618=[""].join("\n");
var outline_f20_8_20618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H74\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEOPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FLESH COLORED PAPULE/NODULE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5433935\">",
"      Sebaceous glands and hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vestibular papillae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acrochordon (skin tag, fibroepithelial polyp, soft fibroma)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5433960\">",
"      Lipomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genital warts (condyloma acuminata)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Molluscum contagiosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Syringoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5433980\">",
"      Lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      WHITE PATCH/PLAQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lichen simplex chronicus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lichen sclerosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vitiligo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DARK LESIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Macule/patch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Acanthosis nigricans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Lentigines and junctional nevi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Papule/nodule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Seborrheic keratoses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dermatofibroma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Extramammary (ectopic) breast",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fox-Fordyce disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Kaposi sarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Compound and intradermal melanocytic nevi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Dysplastic nevi and melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Atypical genital nevi (nevi of special sites)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22535182\">",
"      Cyclists&rsquo; nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Red macule/patch/plaque",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Psoriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Plasma cell vulvitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Atrophic vulvitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Hailey-Hailey",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5434289\">",
"      Erythrasma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Extramammary Paget disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Red papule/nodule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Urticaria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Cherry angioma (Campbell de Morgan lesion)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Angiokeratoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Urethral lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Endometriosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5434296\">",
"      - Varicosities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      PUSTULES, VESICLES, AND EROSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Folliculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Furunculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Candida",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Scabies and insect bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Bullous impetigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Fixed drug reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Blistering diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      ULCER/FISSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Systemic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      Vulvar skin care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      Soaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      Lubricants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      Topical analgesics and oral antihistamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      Estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66\">",
"      Antimicrobial drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67\">",
"      Antiinflammatory agents (oral or topical)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68\">",
"      Combination topical antimicrobial and anti-inflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71\">",
"      Geriatric",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72\">",
"      Immunocompromise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H73\">",
"      Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5412\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5412|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/26/17827\" title=\"picture 1A\">",
"      White plaques of VIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/50/43811\" title=\"picture 1B\">",
"      VIN 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/0/31745\" title=\"picture 2\">",
"      Red macular lesion of VIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/15/20725\" title=\"picture 3\">",
"      Brown macular lesion of VIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/21/19794\" title=\"picture 4\">",
"      SSC and LS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/2/25633\" title=\"picture 5\">",
"      Vulvar papillomatosis papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/0/11265\" title=\"picture 6\">",
"      Acrochordon thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/32/14850\" title=\"picture 7\">",
"      Bartholin gland abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/18/14626\" title=\"picture 8\">",
"      Condyloma acuminata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/12/26818\" title=\"picture 9\">",
"      Condyloma lata syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/10/30887\" title=\"picture 10\">",
"      Molluscum pubic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/5/12369\" title=\"picture 11\">",
"      Syringoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/3/42035\" title=\"picture 12A\">",
"      Lichen simplex chronicus1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/8/42117\" title=\"picture 12B\">",
"      Lichen simplex chronicus2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/14/228\" title=\"picture 12C\">",
"      Lichen simplex chronicus3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/38/42597\" title=\"picture 13\">",
"      Lichen sclerosus vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/35/24127\" title=\"picture 14\">",
"      Vitiligo2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/7/3198\" title=\"picture 15\">",
"      Acanthosis nigricans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/8/21636\" title=\"picture 16A\">",
"      Seborrheic keratosis hyperpigmented",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/56/41859\" title=\"picture 16B\">",
"      Seborrheic keratosis vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/2/9251\" title=\"picture 17\">",
"      Fox Fordyce disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/14/10467\" title=\"picture 18A\">",
"      Contact derm vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/6/12385\" title=\"picture 18B\">",
"      Contact derm vulva2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/48/33540\" title=\"picture 19\">",
"      Vulvar psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/51/13110\" title=\"picture 20A\">",
"      Hypertrophic lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40530\" title=\"picture 20B\">",
"      Erosive lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/14/12517\" title=\"picture 21A\">",
"      Plasma cell vulvitis1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/26/43429\" title=\"picture 21B\">",
"      Plasma cell vulvitis2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/45/13023\" title=\"picture 22\">",
"      Atrophy vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/63/35828\" title=\"picture 23\">",
"      Hailey Hailey",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/51/31541\" title=\"picture 24A\">",
"      Candidiasis vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/20/13635\" title=\"picture 24B\">",
"      Candidiasis vulva2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/58/20391\" title=\"picture 25\">",
"      Pagets vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/55/41841\" title=\"picture 26\">",
"      Cherry angioma2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/11/9399\" title=\"picture 27\">",
"      Angiokeratoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/37/19024\" title=\"picture 28\">",
"      Folliculitis vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/25/38289\" title=\"picture 29\">",
"      Hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/24/6531\" title=\"picture 30A\">",
"      HSV primary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/40/29319\" title=\"picture 30B\">",
"      Recurrent HSV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/26/32166\" title=\"picture 30C\">",
"      HSV folliculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/10/6305\" title=\"picture 31\">",
"      Scabies vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/39/42612\" title=\"picture 32\">",
"      Fixed drug rx vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/1/9236\" title=\"picture 33A\">",
"      Bullous pemphigoid vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/11/44211\" title=\"picture 33B\">",
"      Bullous pemphigoid vulva2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/30/11746\" title=\"picture 34\">",
"      Pemphigoid vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/57/9105\" title=\"picture 35\">",
"      Chancre",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/28/31169\" title=\"picture 36\">",
"      Condylomata lata2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/21/44372\" title=\"picture 37\">",
"      Behcets vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/10/1188\" title=\"picture 38A\">",
"      Crohns vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/21/41299\" title=\"picture 38B\">",
"      Crohns vulva2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/32/30212\" title=\"picture 39\">",
"      Crohns disease of vulva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/49/29457\" title=\"picture 40\">",
"      EB virus vulva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5412|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/29/34267\" title=\"table 1\">",
"      Morphologic terms vulvar lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/11/12477\" title=\"table 2A\">",
"      Common vulvar lesions 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/5/1117\" title=\"table 2B\">",
"      Common vulvar lesions 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/32/40460\" title=\"table 3\">",
"      Rare vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/49/36635\" title=\"table 4\">",
"      Healthy vulval hygiene practice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/60/9164\" title=\"table 5\">",
"      Vulvar lesion immunocompromise",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27897?source=related_link\">",
"      Acanthosis nigricans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=related_link\">",
"      Approach to the patient with pustular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/17/43287?source=related_link\">",
"      Benign pigmented skin lesions other than melanocytic nevi (moles)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=related_link\">",
"      Breast development and morphology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=related_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5336?source=related_link\">",
"      Dermatitis of the vulva",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37349?source=related_link\">",
"      Diagnostic evaluation of vulvar lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22375?source=related_link\">",
"      Disorders of Bartholin gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=related_link\">",
"      Folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21846?source=related_link\">",
"      Impetigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28216?source=related_link\">",
"      Insect bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21063?source=related_link\">",
"      Lymphogranuloma venereum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/42/4774?source=related_link\">",
"      Management of intergluteal pilonidal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/43/6842?source=related_link\">",
"      Molluscum contagiosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/553?source=related_link\">",
"      Overview of benign lesions of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/7/6265?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=related_link\">",
"      Skin abscesses, furuncles, and carbuncles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27178?source=related_link\">",
"      Treatment of vulvar and vaginal warts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21193?source=related_link\">",
"      Vitiligo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9303?source=related_link\">",
"      Vulvar cancer: Clinical manifestations, diagnosis, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32952?source=related_link\">",
"      Vulvar intraepithelial neoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36952?source=related_link\">",
"      Vulvar lichen planus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_8_20619="ECG of prior MI";
var content_f20_8_20619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ECG changes associated with prior myocardial infarction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Any Q-wave in leads V",
"        <sub>",
"         2",
"        </sub>",
"        -V",
"        <sub>",
"         3",
"        </sub>",
"        &ge;0.02 s or QS complex in leads V",
"        <sub>",
"         2",
"        </sub>",
"        and V",
"        <sub>",
"         3",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Q-wave &ge;0.03 s and &ge;0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V",
"        <sub>",
"         4",
"        </sub>",
"        -V",
"        <sub>",
"         6",
"        </sub>",
"        in any two leads of a contiguous lead grouping (I, aVL,V",
"        <sub>",
"         6",
"        </sub>",
"        ; V",
"        <sub>",
"         4",
"        </sub>",
"        -V",
"        <sub>",
"         6",
"        </sub>",
"        ; II, III, and aVF)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R-wave &ge;0.04 s in V",
"        <sub>",
"         1",
"        </sub>",
"        -V",
"        <sub>",
"         2",
"        </sub>",
"        and R/S &ge;1 with a concordant positive T-wave in the absence of a conduction defect",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The same criteria are used for supplemental leads V",
"     <sub>",
"      7",
"     </sub>",
"     -V",
"     <sub>",
"      9",
"     </sub>",
"     , and for the Cabrera frontal plane lead grouping.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Eur Heart J 2007; 28:2525. Copyright &copy;2007 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20619=[""].join("\n");
var outline_f20_8_20619=null;
var title_f20_8_20620="Common cold treatments in pregnancy 4";
var content_f20_8_20620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect in randomly controlled trial",
"        <br/>",
"        (not pregnant)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancy data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Decongestants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Intranasal:",
"        </p>",
"        <p>",
"         Oxymetazoline",
"        </p>",
"        <p>",
"         Xylometazoline",
"        </p>",
"        Pheniramine",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Short lived mild relief of obstruction with single use. No evidence of sustained effects.",
"        </p>",
"        Spray decongestants associated with rebound effects upon withdrawal.",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         All FDA pregnancy classification C.",
"        </p>",
"        <p>",
"         Most commonly used decongestants are in need of further study before they can be definitively considered safe in pregnancy. Present data is variable but these agents probably represent a low risk.",
"        </p>",
"        <p>",
"         Oxymetazoline is the preferred intranasal agent but use for mild symptoms should be discouraged in pregnancy. No clear human teratogenic effect and no effect on uterine blood flow in the setting of normal nasal mucosa but concerns exist about its possible effects on uterine blood flow in the setting of overuse, inflamed nasal mucosa and in cases were poor placental perfusion is already suspected.",
"        </p>",
"        <p>",
"         Pseudoephedrine should be avoided in the first trimester. Two studies have suggested an increased risk of gastroschisis. Later in pregnancy, it is probably the preferred oral agent among the oral decongestants. This agent is less likely to raise blood pressure than the other oral decongestants.",
"        </p>",
"        <p>",
"         Ephedrine is teratogenic in chicks even at small doses. No evidence of human teratogenesis but data are limited.",
"        </p>",
"        Phenylephrine has been associated with a wide range of congenital anomalies in humans and dramatic effects on uterine blood flow in sheep. This agent should be avoided at all stages of pregnancy. The uterine vessels are maximally dilated and have only alpha-adrenergic receptors. The alpha-adrenergic stimulant phenylephrine will cause constriction of these vessels, resulting in reduced uterine blood flow, fetal hypoxia, and subsequent bradycardia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Oral:",
"        </p>",
"        <p>",
"         Pseudoephedrine",
"        </p>",
"        <p>",
"         Ephedrine",
"        </p>",
"        Phenylephrine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20620=[""].join("\n");
var outline_f20_8_20620=null;
var title_f20_8_20621="Mood timeline";
var content_f20_8_20621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F84011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F84011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Mood timeline",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 447px; background-image: url(data:image/gif;base64,R0lGODlhDgK/AcQAAP///wAAAGZmZiIiIpmZmd3d3YiIiLu7u0RERBEREe7u7jMzM8zMzHd3d1VVVaqqqn9/fwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAOAr8BAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t6MGAbsDBikCArjCw1IGCCIEAw0owMTOz0nGIwUBBQC7AQMMB9jHBAkBCQQiCMfQ5+gz0iMD4yMCDgDNAAcD1g8JCgDl6f3+K+tEtAPQAFyAY/N0Yav2r6HDEgGpFTAw4AAAaQkXPNzI8aK5ZMsaaFSw4FgDc9zG/zHQuM9cx5fDFIbzBaDAgnAlATAAd8yAwWAtR0BYSLSo0aNIkypdig0CzKdQo0qdSrWq1atYs2rdyrWr169gw4odS7as2bNo06pdy7at27dw48qdS7eu3bt48+rdy7ev37+AAwseTLiw4cOIEytezLix48eQI0ueTLmy5cuYM2vezLmz58+gQ4seTbq06dOoU6tezbq169ewY8ueTbu27du4c5N2Gpg3YN9oAggWHph4GuN/kftVboY5X+d7oY+Rnpc6XutgsNvVXpd7F+9zwcsVr4U8XPNv0V9R35Y9W/dU4KuVn5Z+FPtn8ZvV74Q/Wf9jAbiEgGERCJaBSCDolf+CXTFYhINbQaiVhEJQiJWFV2H4g4ZVcUiVhzyAKJWIUZGYg4lPoQiTijaw2JGLHME4g4wP0eiQjTDg+I+O/vDYgo/pAImOkCoQCY2RzyB5gpLEMDmMkyQwJeWUVFZp5ZVYZqnlllx26eWXYIYp5phkQjmCmbegaYuaatbSJi1sDienGm/OUqcscRY353F7JrfGnbEACkuegAn6CqF+6klnn8v9yWhfiDaqKJ+TJkppoY+WYagrm7YSKaSZktEpK6Ou8ulzoU6XanWOVirppZbGekapqtCayqnRrRqGrajweoqawPkVbF/D6mbsscgmq+yyzDbr7LPQRivttNRWa+3/tdh+cQA4CViERAHdIqGAA7uIg4QA2NCEREpIILCQt0Uks8sR7i50xDe7qEtEPfkmcRIJ9boURgK++HTuLvAWYRMDBEG4AMMEBKDPEeCaS6++RuDjzhLwGEHNAwA8EADDRChgLjcJC0HNQSNQpIACvYjBgHEjJxFAykfUs4QBLBkBM0UbF4EAxkUsQDTFDClcswJJD8HNCA4cHURAUYtgQDxhJMMOyAnibIQA1iARcc30LjMQven6nM0uC0x8hANAGRExAgsErXIA7iwQdxEBnU1Az19oLRDXR9y8M8lKfOP2EP8CcHYSESN+N8gkLZNz00QUUBEDDgywuBBjZ2O5/xF9u/O3zMQxLfmDXg+BAOEDtu5DvdjsXbjsPZAdkNC2D1G6EgnATgTVNDWA9cAFJ6CE4RQbrcQBCFjj0+dFPJ75AtLnYwQ/P+ecQNgZG46yuHRH45LL3YuxbTi4+4AuNpcvZHcQBdRb0RLWD6GA/e3zYNMux6ue1IQgkwH6QCEOoB79FkKTgGXrgRCMoAQnSMEKWvCCGMygBjfIwQ568IMgDKEIR0jCEprwhChMoQpXyMIWunBC/cuKRAgjOEAwbywzHEwN/3BDseRQMDuMQsd0Uo2V7GIZyZiZu7yFgL3tj20K4AYU6TGAcPRwK/8LQDBmKADsySQYAkAJ5qRCDf+SwQ0A+DIXMHShOACYLGjfuInhvigQB1KjXr4Iowi4AT4ZzMwaxjOZRcB1gG/QpGM/vMgA3Bg9EvTCZL5gWgylwg9wEUAiXVxcGcsoj95J5Yyqq8c98tFFd8QsiN8YRxdJwMkBHMOS1PCFyArAyXnUwGgme4AUsUGAGnJDAY0bATeAoY8CvC8ABniaCK4IQxEY745t2yPtLIKABkgSK/hQAM8uQhRjxm2bziOB4LQGPWxY5GzAyOFAqnlNGySDnBIT5yJHUM1wlUABwBiZA7C3j2TSbJIl8tYzA3ATbyUAa+JLQDCv0o6BbJMEtoSk9uSJjEUedJnndIcDGpDD4NH/Q6ECo4HJCObGBARjXIWcJzKyYQIBRDJ4C1gGAx6JNzQyMyv82Mklq+ETBjANZBHzVhXnRxWfaI9dK+kkRLVognF6LgBANVzMdnIATrbRcTXFAbomdgA5Ri+IWZUnAD9K0FOy7aZYyeIWGdJThSzRaipNawBG55NdgHFvfGzqPLXmVqkaxBfU4Ba8KLKEqy4mZmzRIw2sl0iBGDAIiF2MYdNCDYCagLFjnOwLN8vZznr2s6ANrWhHS9rSmva0qE2talfL2ta69rWwja1sZ0vb2tr2trjNrW53y9ve+va3wA2ucIdL3OIa97jITa5yl8vc5jr3udCNrnSnS93qWve6/9jNrna3y93ueve74A2veMdL3vKa97zoTa9618ve9rr3vfCNr3znOxtb3sC+RMBv9YiqgyCeYGz8zVpc35C/JZCEpSVo7IwsK4cnAlCB+v3vgGuStAgHwcI9UGeAceBfE1hsB4TU6wtERgKF8BOiQOlwCTDshAJfdsOkm7AIJKJgF5sArXpwAEpOvGJPijjBFfYxEFgM4qTZOAcqHgHT+qhVhP2YBVU0zswY5oAAKhWNMu7xFY7MDhgXoQE+pvEYHeflazA4DuEUJ7dUedKA6cOIyLQXPc3ZxSraQydyHB0yEiBHizgVjXwORwPsbI0ugoOfcEaiNpg6DTmuFY8lmP+mK3dhjkSXAF81hbMvsKENLDuTbZKjXRkHsEhyEVQfA/CqqaXGTHsppNMmUKZH9qg8YXYjjk7eZdt2KbA14s3SuA5XErXoYAS8rF7RbACoHefAAmLabpNmGTezwTDnTQ8AHmUHTQj7aojtNa67NECxFSCRabYsXWrdYxXBYRFOM6Cy5BAyGyKmN8uJMmSkDMbQRIBLkh5AAP7NYRcZpgxB1sSee1alRv6cyn3cTxny4KfeDE5IQ5qgkuKgBhLjOQ0jG/tjFEc4tsdBAGv6e28d46s5FjpDaghAHxSxht6YHcUAxCNiCmSm4MY36BPIeh7UWNw8Gr5KR+axd6Us6SD/u/UNi/Tc4v3ktwEIu7+JrPwYriQ3VMksAnOVvARZ/xjPF2m8fUB1Zov7hkAIMHZPu/0dQNk3AIwmZiZzPSiWhKQbe9gxRI45DmBewPdksgtvXmMhApD12zsetnkAY5e7gOO33a41wa2jGUOvCFF6KWPmDdQaidTw2iEf1n3obRyKJ4hBvLFI2iF4xgzJodzxcXfDKdjMP16H6mJtHKBzXASZr2hNjnn0lgKF9JyHfQFqSJTEa/HlZuf03QdyNroB/MVr1/3IsqnQqAGupA/IpvYZ8GcULxPxdcc+7gniAFkbriCUpofEFnoHoz0U7teAneIDHmTgO1+BlLdIDDdP/5d3V1azAL9EUTcmUA7QcpgjemSWgChAAF3UfshBERYhDVpTTSjggGEze8pzNrb3dzpHgOaweyUga+tAe+YXgACwT9awb/o1DxIofESkAMwnPPiELgzAgY5kSuPwOBS4AFZ2Nu0wfthmPDshdyVWDgVzgiNTfviXf6xUDTXmDp5ngWdyABg4a/tQEGdGBnK3LQeAVBrRDHQDc+J2ctl0T8zjeC9nUm7UfgqoNfhQAPsjgCbof/IQDySxhifVfh2WUxkXe5jTTkZIACYTiPCyMBfRNicnEm6UE3yVABCzNx4IV3g4cyI4SCSIM204PgIgY7I2ZS9oZY3zZzGlEzFDf/9XtohzWEi1pkc1lIYXYQAuBX49hUbBkIhzB1gP84hgB4SiOE/kAjI3sToUxhDFiG94iAADNg+2OHUS0U4kEE6EqIg1FVSSSBIfgWD8IAd1NRNW8xNKVT9sYxH8gkwHphzv829A0QxdRWl9VH4Bo4dWYw6Yt3p75FXLJ2PplolLdTO+OI8HAT7jwgvqGGUG8D98xnrAVy76IpAvOEWdSGFMdkzK0Y7TBmuO1A1WwzZMthMH8WfrswBTxRMtSA/+iGn8VEPoSFApNVbyIJHTR3L5Ymr384Nr15Ekc20GcwJNdG7URg6UFo1AEZMIyEVONgJj05COtlIEdTMOmRPL5A7/4dhbSUYG8CYGmuVbWzkGiiUGkUVfZolBKpaVMsBlPXBgExaWU0hPIRUEVikJatk14wMDuhAFPmF3RAaXdkB43AGYa1lmOkBYEoaRQNZ48kZAnnMCRFYGkdmBf2czljWZOjCZVWZ8K0CYdLA7LuCZMMCWPABmE7hIjSVwjRkEH6Zlb4CZJnB7lgkDsKlVq0lEGdmYoimOAqM5ywAuDXkQ/QJPU4R5KJkNfcSCJLVN0eYN2vNGHcdEwdBtV2Zf4QZsrWdOc4YwdYacSvVsJFB2M2MRG3V41NaVQzkCaCcCcOZ8lDZsL+dmDtY27VkTUUlm5NKDUwSZgkdQyiZtwBZo/4bTnrwGn3A4bUw1Tc0QkMKJTClADY7WZ4xEafrAL+w2Q2lUhtiwa7dmjMV5nHcGnhO4ZrzWMARld2kGfP2JaHnmdt22ezp2g3EgmET0ADMXSyFTDUEUM8ZJcHoWSgT1gmbzcVt3StEYDxLRdgdqfiGXUopZhY0XjBDXDF6nZ7SnC8uQbcAXD35Xjyp1RpxzZVAnd/a3SFUHpvGAcUGIAAxDdY3Enz7FZ7QEVU1KdBqBpmJKUtWJiSOjmnhXiBsHgBrHTXmkEWS6hpFEldUwPlNndGK6SDE3d2AkpVlKcnpGAveWTQlxZ3RYAmcEURIXh0vnpG3XbxJzf28AmjbFEv8apjXGlDaYF4+2YzQNUBA7ATK+CE4Y80v/Mn5Lin/I56pj5KdKhYan54Yr0VPxBH8sw6shVUM+kYuPeiaIN0zQF600kYV3Z60AeGVy1w7BOnnYyodvd6DlhDB+moUUuZjyJ3zN535VxVO9SXzTCoJ7anrXhwKCaXhR9wu2k3nh6oWqYzwP4ITlOaNzKTLR1FEPoDUwGHWxSq4t0zmc4wDa44sSRT31lIFQyAC/yoc16Gmp2X/FmmIV6KkFgW0x2oXrsLGXFlceC407aINUSAI7WDMx+1QMeHdulE/KSK7fyna/54I6EUaeE3zkSqUIFa+MuX6f96SxyYzEoTVbZ2v/WygRu/OwMphirUcTtLekQ2hlLfN90mhAnzqFPBOyKicCqrMTLmUMIucGoDkzNoqkNaM4WrOKM1V8H0tEGiEyWOOLNelJETNPzSiJK/GvJyWHKKU11si2byirneSIqMpNIeGg3WiVhWsC67kPqDd/H6FS04iLL1Wwn7s/x6BTd5eLuTR3IVW2aweLjTt5CHC6qahSiDtxWxdU7YSGqVuIoMcQBaFJUit8o8s0OMm0jMozMtWKoatIm2iAkxuM2zS8mJppGtE4kdp+efmLK+aH/caI8GQRo9h1EsM0tbaXcttNEAecgcU+nnaSPCq9+kVSeneTe1SZYUWdmpMNM9eC/wb5VfP0jgMJj3xITDqZMuMpfwxTlS5ReiOgpwWkEzwBk8g2kzaHoMBoVz2JZWOFvK4ZtCxJj382wSRZuyrVv6k2nZRmOO+4oFGZif/LeO0qshdsU1PJtNPWLfLrCycsOKYWTXCYkNlgETPcMuZ4whV5onn5RyvGjyN8kJbHC2ZkDgiANeqrB7JZBGN5aRMFB1+pSN2qBDsxxmUQt2OAxjWwmaOwxUPQlZf1WGhQliVQl1CAi28wU2igx4f5PWf5x4AcyII8yIRcyIZ8yIicyIq8yIzcyI78yJAcyZI8yZRMB0NRJpicyZq8yZzcyZ78yaAcymJSLJVcyqZ8yqicyv+qvMqs3Mqu/MqwHMuyPMu0XMu2fMu4nMu6vMu8zAqXLMrAHMzCPMzEXMzGfMxTQsq9vMzM3MzO/MzQHM3SPM3UXM3WfM3YnM3avM3c3M3e/M3N/MvIPM7kXM7mfM7oPM7KDM7s3M7u/M7wHM/yPM/0XM/2fM/4nM/6vM/83M/+/M8AHdDinM4EXdAGfdAIndALsc4B3dAO/dAQHdESPdEUXdEWfdEYndEavdEc3dEe/dEgHdJAMNAKXdImfdIondJfwtAi3dIu/dIwHdMyPdM0XdM2fdM4ndM6vdM83dM+/dO+rNJCPdREXdRCzdJAndRKvdRM3dRO/dRQHdVSPdU+VF3VVn3VWJ3VWr3Vq0HSRv3VYB3WYh3KSM3VZn3WaJ3War3WbN3Wbv3WcB3Xcj3XdF3Xdn3XeJ3Xej0XIQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20621=[""].join("\n");
var outline_f20_8_20621=null;
var title_f20_8_20622="Dose response cessation";
var content_f20_8_20622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Dose response of smoking cessation rates according to the effort clinicians make with patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 481px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Combined results of 43 studies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher, RH, Fletcher, SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore 2005. Copyright &copy; 2005 Lippincott Williams and Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20622=[""].join("\n");
var outline_f20_8_20622=null;
var title_f20_8_20623="Galactocele";
var content_f20_8_20623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Galactocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two needle marks resulting from bi-weekly aspiration are visible to the right of the areola.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_8_20623=[""].join("\n");
var outline_f20_8_20623=null;
